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            Siddha  medicine  is  one of  the  most  ancient mother medicine of   medical  
systems  of  India.The word siddha comes from the Tamil word perfection .It equals 
to emphasis on the body,mind and spirit and strives to restore the innate harmony of 
the individual.      Siddha   is the  mother medicine  of  ancient Tamil of  Southern 
peninsula. The  word  siddha  means  established  Truth. The  persons  who  were  
associated  with  establishing  such  a  school  of  thought  were  known  as  siddhars.  
Many of the siddhars devotes saivaities yet,poonaikannar, a French priest, was a 
siddhar.Yakobu, a Muslim, was a siddhar .  Siddha, gained recognition and its own 
popularity in the world of complementary alternative medicine. They  recorded  their  
mystic  findings  in  medicine, yoga, rejuvenatory   techniques  and  astrology  in  
Tamil. Fundamental principles  of  siddha  include  theories  of  five  elements  
(Aimpootham), and  three  forces /faults (Muthathu/Mukkutram).The  eight  methods  
of  Examination  (EnnvagaiThervugal) is used to determine diagnosis,etiology, 
treatment, and prognosis. Siddha  has  safe  herbal  and  herbo  mineral  treatment  for  
Psoriasis,Eczema, Alopecia, Diabetic Ulcer,Warts,Vitiligo,Pemphigus,Pompholyx, 
Leprosy and  many  more  very  common  and  rare  diseases. Lifestyle modifications 
including food habits are more important in siddha medicine. 
             Venpadai is  popularly  known  as  “vitiligo” has  been  a  challenge  to  the  
medical  world.Siddhars classified the diseases into 4448 types. Skin diseases are also 
include in these types. Venpadai  or  venkuttam  is  also  called  “Swethakuttam” 
which  is  one  of  the  18  varieties  of  “kuttam” noted  in  yugichinthamani.The  
diseases  were  caused  by  psychosomatic problems. So  that  they  had  advised  to  
control  one’s  mind  to  get  out  of  stress. This was quoted by “Agasthiyar” as 
follows,    
lelK!osl<jlbieiz<!lf<kqvR<!oshqg<gOu{<mi< < < < < << < < < < << < < < < < !
lelK!osl<jlbieiz<!uiBju< << << < !dbi<k<kOu{<mi< < << < << < < !
lelK!osl<jlbieiz<!uisqjb< << << < !fqXk<kOu{<mi< << << < !
lelK!osl<jlbieiz<!lf<kqvR<!osl<jlbiOl//< < < < << < < < << < < < < !
!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.ngk<kqbi<< << << <!
               Vitiligo is a polygenic,multifactorial disorder that involves multiple 
susceptibility gene12-14. Epidemiological  studies  have  shown  that  family  
clustering  of  vitiligo  occurs  frequently. There is  also  an  increased  risk  of  
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vitiligo  in  1st  degree relatives  and  high  concordance  in  monozygotic  
twins14,15.Vitiligo is  an  acquired  depigmenting disorder  of  the  skin  resulting  
from  loss  of  functional  melanocytes. It  is  a  common  disorder  affecting  between  
0.5% to  2.0%  of  the  general  population (A review of the world wide prevalence of 
vitiligo in children).   It  can  have  a  variable  age  of  onset, but  many  studies  have  
reported  that  around  50%  of  the  patients  have  an  onset  before the  age  of  18 
yrs  and  a  quarter  before the  age  of  8years.Everything  in  the  universe  is  made  
up  of  5 basic  elements [pancha pootham]  although  sattaimunignanam  goes  to  
say,  “MICROSOME  REFLECTS  MACROSOME” this  means to  say  whatever  
happens  in  outside  the  universe  also  happens  in  the  human  body/ 
 The  Paediatric Vitiligo  differs  from  the  adults  by  showing  an  increased  
incidence  in  females. The vitiligo in Children is  often  associated  with  marked  
psychological   and   long  lasting  impact  on  the  self-esteem  of   the  children  and  
their  parents. Hence a satisfactory treatment is very essential. Treatment   of  vitiligo  
is  definitely  a  tough  challenge  for  the   dermatologists  more  so  in  the  
background  of   childhood  vitiligo. Although  multiple  therapeutic  modalities  are  
available  in  the  therapeutic  armamentarium  not  all  can  be  used  in  children. The 
disease varies between 0.1-4percent of the world population. Many  etiological  
hypothesis   have  been  put  forward  to  explain  vitiligo, among  which   the  most  
compelling  one  is  a  combination  of   genetic  and  immunologic  factors  which  
interact  with  each  other  resulting  in  an  autoimmune  melanocyte  destruction. It  
is  my  attempt  to  find  a  better  medication  to  the  vitiligo  patient  to make them  a 




2. AIM AND OBJECTIVE 
Aim :  
 The aim of the dissertation work is to be analyse the selected disease 
Venpadai noi (Vitiligo) both clinically and experimentally with the trial drug of 
Ilagu Seena Chooranam. 
 
Objective :  
1. To collect the literature of both siddha and modern aspects of the disease 
Vitiligo.  
2. To study the clinical course of the disease with observation on the etiology, 
classification, pathology, prognosis, complications and treatment by siddha 
aspect 
3. To have an idea about the incidence of the disease with age, occupation, 
economical status and climate conditions and hereditary.  
4. To expose the clinical diagnostic methods mentioned by siddhars to know how 
the disease manifest due to deranged mukkutram, poripulangal, Elu udal 
thathukkal and Envagai thervugal.   
5. To have the modern parameters to confirm the diagnosis and prognosis of the 
disease.  
6. To have a clinical trial on the disease Venpadai with the siddha drug Ilagu 
Seena Chooranam. 
7. To evaluate the  
• Bio chemical analysis  










!! yV! leqkEjmb! Hx! npjg! fqi<{bqh<hK! -k<Okiz<! NGl<?! hx<hz!
fqxr<gtqz<! njlf<K! lif<ki<kl<! usQgv! Okix<xk<kqx<G! Nkivlig! uqtr<Gl<?!
dml<hqe<!lqgh<!ohiqb?!lqg!fQtlie!dXh<H!Okiz<!NGl</!
!! Okizqz<!d{<miGl<! sqX!uqgx<hl<!%m! hiIjubiti<gtqe<! Okix<xk<kqx<G!
uqgivlig! oke<hMuK! -bx<jg/! ! Okizqe<! fqxl<! gVjlObi! nz<zK!
osl<jlObi! hzviZl<! yk<Kg<! ogit<th<hMl<! Oujtbqz<?! -bx<jg! fqxl<! lixq!




hii<h<hkx<G! yV! OuXhimie! Okix<xl<! d{<miukiz<! -kx<G! lVk<Kul<! fic!
hzVl<!lVk<Kuljeg<G!uVgqxii<gt</!




ou{<Gm<ml<?! ! okiPOfib<! Lkzqb! hq{qgt<! biUl<! -h<hGh<hqEt<! nmr<Gl</!
weOu!Gm<ml<!we<x!osiz<!kx<OhiK!upg<gqz<!ohVOfijbg<!Gxqh<hK!Ohize<xq!
hz!Okix<hq{qgjtBl<!%m<mligg<!Gxqg<Gl<!ohiKh<ohbi<!NGl</!
Ofib<!hGh<H;< << << < !!
!!!!!ou{<hjm! Ofijbg<!Gx<x!ntuig!uik!ou{<hjm,! hqk<k! ou{<hjm,!
gh! ou{<hjm! we<x! &e<xigg<! %xh<hm<Mt<tK/! -kEme<! Olg!
ou{<hjmjbBl<! %m<c! ogit<tzil</! Olg! OfibqZl<! ,okiP! OfibqeiZl<!
Wx<hMl<! ou{<hjmgt<! okix<xg<%cbe/! Wjeb! okix<xikju/! weqEl<, sqz!
Oujt!hvl<hjv!Ofibig!uVuK{<M/!okiP!OfibqZl<!ou{<hjm!gi{<hK{<M/!
ohbi<g<giv{l<;< < << < << < < !
!!!!!!dmzqz<! -bx<jgg<G! lixie! ouTh<jhB{<mig<Gukiz<! ou{<Gm<m!
Ofib<!we<X!ohbi<!ohx<xK/!-h<hq{q!Lg<Gx<x!OuXhim<miZ{<miuK/!Gx<xr<gt<!
Lke<!Lkzqz<!GVkqjbBl<,-v{<miukigs<!sjkjbBl<!kig<gqh<!hqe<ei<!Okizqe<!
















! dmzqz<! lr<gqb! ou{<jlbie! fqxLt<t! hz! ntuie! Ht<tqgTl<?!
hjmgTl<! uqgivligg<! gi[uOkiM! sqzOujt! nu<uqmk<kqz<! lbqVl<!
ouTk<Kg<gi{<hkie!yV!Ofib<!!
!
)sqk<k!lVk<Kul<!sqxh<H*!< < < << < < << < < < h/w{</;345<<< !
!
! dml<hqz<!um<m!um<mlib<h<!hzuqmr<gtqz<!out<jt!uqPf<K!uqgivlig<gq!
njugtqe<! Sx<Oxivl<! kck<K! uqvquib<h<! hmv<f<K! nSX{<migq! dkqVl<! Yv<!
Gm<ml<!
!
. T.V. sil<hsqul<hqt<jt!ngvikq!!h/w{</22:9< < < << < < << < < < !
!









• -k<Okiz<! Ofib<! g{<muqmk<kqz<! Olz<! Okizqz<! gi[l<! fqxlqgt<! we<x!








“uqbikqBt<<<<!&uiX!uqtr<gqb!Gm<mr<!Ogt<< < < << < < << < < <!
!Sbikqg<!gqvf<kq!Spe<!Olgk<kiz< < < << < < << < < < iXl<<<<!
!hbikq!l{<[t<<< h<< <<!hz!u{<c{iozm<Ml<< < << < << < <!











































!! lqGf<k! ouh<hl<?! ! lqGf<k! sQktl<?! nzi<\q?! lf<kl<?! uif<kq?! fqk<kqjv!
ogit<tijl?!kuqM?!l{<gt<?!lbqi<!sikk<Kme<!hVGkz</!
!! nuvui<! osb<gqe<x! nki<ll<?! ohiqObijv! lkqbijl?! squizbk<kqz<!
sq]<mr<gt<! osb<hui<gt<?! squ! fqf<jk! h{<[Ouii<?! Gjxf<k! %zq! ogiMh<Ohii<?!
H,i<u! ge<lk<kqeiZl<?! ohiqObii<gt<! sihk<kqeiZl<! hikgr<gt<! lekiqb!
h{<[Ouii<g<Gl<!ou{<hjm!OfibieK!uvg<%Ml</!
!















!! lzvik! nVl<jh! ogib<kz<?! sQuosf<K! ujkgt<! osb<kz<?! ff<kuel<!
H,R<oscgt<!oum<mz<!Ngqbux<xqeiZl<!ou{<hjm!OfibieK!uvg<%Ml</!
!




















• HP! Ohie<x! F{<gqVlqgtiz<! fie<Gl<! Ng! 29! ujg! Okiz<Ofib<!
d{<miGl</!
!














• fe<xq! lxk<kz<! Ohie<x! giv{r<gtiZl<! Gm<m! Ovigl<! uVl<! we!
ke<uf<kqvq!%Xgqxiv</!
!





















lzszk<jk! nmg<Gkz<?! uqmfQi<hVgz<! Ngqbux<xqeiZl<! ou{<hjm! OfibieK!
uvg<%Ml</!
!











!! hqk<k! lqGkqbie!d{U!dm<ogi{<miz<!dmz<! ouTk<kz<,! fqxg<GjxU!
Ohie<xju! Wx<hMl</! Htqh<H!d{U! ogit<tz<?! nx<h!d{<c!Ngqbux<xqeiZl<!
ou{<hjm!OfibieK!uvg<%Ml</!
!












! !uqmg<gvh<hie<?! uqmfQi<?! S,jz?! SOvi{qkk<kiz<! kiK! ogm<M! kch<H!
d{<miGl</!
ujggt<;<<< !
sqk<kv<!nXju!< << << < lVk<Kuk<kqz<;< < << < << < < !





sqk<k!lVk<Kul<!sqxh<H!F~zqe<hc< < < < << < < < << < < < < !






T/V/!sil<hsqul<!hqt<jt!ng< < << < << < < vikqbqz<;< << !
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29/ SOuk!Gm<ml<!)ou{<!Gm<ml<*< < < < << < < < << < < < < !










































Gm<ml<!29< << << < .z<< <<!






osgvis!Osgv!juk<kqbl<!wEl<!F~zqz<< < < << < < << < < <!
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GxqG{r<gt<< << << <!
2* sqxh<H!lVk<Ku!F~zqe<hc< < << < << < < !
ou{<hjm!Ofijb!Gx<x!ntuig!uik!ou{<hjm?!hqk<k!ou{<hjm?!
gh! ou{<hjm! we<x! &e<xig! %xh<hm<Mt<tK/! ! -kEme<! Olg!
ou{<hjmjbBl<! %m<cg<ogit<tzil</! ! Olg! OfibqeiZl<?! okiP!
OfibqeiZl<! Wx<hMl<! ou{<hjmgt<! okix<xg<%cbju/! ! Wjebe!






!! -K! osiv! osivk<Ks<! squf<K! ogiR<sl<! gVjls<! sibZme<!
ouTk<kqVg<Gl</!
!
3* hqk<k!ou{<hjm!;!< << << < !




!! -K! Kl<jh! lzv<! Ohiz! ou{<jlbig! ouTk<K?! ogiR<sl<! kck<Kh<!
hvUl</!!hvUl<!-mr<gtqz<!fjls<sz<!d{<miGl</!
-l<&e<X! ujgk<! Okix<! hq{qgtqZl<! GVkq?! lilqsl<?! ogiPh<H! Ngqb!
dmz<! kiKg<gjth<! hx<xqeiz<?! hiv<jug<G! nVuVh<Hl<?! uqgivLl<! Ne!




!! -K! ogiXg<G! Ofib<! dmzqx<! gzf<k?! fie<G! Lkz<! NX!
likr<gTg<Gh<hqe<! Okie<XgqxK/! ! -K! utv<f<k! fqjzbqz<?! ogiXg<G! Ofib<!
lQTl<! OhiK! d{<migqxK/! ! -u<uqk! ou{<hjm! nOeglig! gPk<kqe<! hqe<!
Hxh<hGkqgtqz<! gi[gqxK/! ! sqzOujt! Okit<! ohiVk<K?! LKgqe<! Olx<higl<!
Ngqb!-mr<gtqZl<?!OkijzBl<!hvuzig!hikqg<gqe<xK/!
!! Olg! ou{<hjmbiz<! hikqg<gh<hm<m! hGkqgt<?! fqxlqgt<! -e<xq! ouTk<k!
sqX!sqX!hjmgjtg<!gim<Ml</! !-h<hjmgtqe<!Sx<X!uvl<H!lR<st<!gzf<k!lv!
fqxliguiuK?!-t!lv!fqxliguiuK!dt<t?!fqxlq!nkqgvqk<k!ujtbr<gTme<!
gi[gqxK/! ! ! -h<hjmgt<! um<mligUl<?! -v{<M! Lkz<! &e<X! lqz<zq! lQm<mv<!
uqm<mLl<!nkx<Gl<! Olx<hm<m!ntUgtqZl<!d{<miGl</! !-f<Ofibqz<! fqxlqbx<x!
hGkqgtqZl<?! fqxl<! lqg<gh<hGkqgTl<! lixq! lixq! fqjxf<K! Osv<f<K! gi{<hkiz<!
Okiz<! g{<[t<t! sz<zjm! Ohie<X! Okix<xltqg<Gl</! ! -f<Ofib<! oh{<gtqz<!
nkqgligg<!gi{h<hMgqxK/!!-K!hzlikr<gtiuK!hz!N{<MgtiuK!dmzqz<!
nh<hcOb! -Vg<Gl</! ! ogiXg<G! Ofib<g<gie! lVk<Kul<! osb<b! olKuigg<!
GjxBl</!
!! -ju! kuqv! dmz<! LPuKl<! fqxlqgtx<Xh<! Ohib<! ouTh<hig! gi[l</!!
ouTh<Hmz<! we<x! yV! fqjzBl<! sqzvqz<! gi{h<hMgqxK/! ! -uv<gtqe<! dmz<!
LPuKl<! ouTk<Kg<! gi{<hOkiM?! dmzqe<! lbqv<! hPh<higuiuK!
out<jtbiguiuK!-Vg<Gl</!!-u<ujgbie!ouTh<Hmz<!ogi{<muv<gt<!-tl<!




3* ke<uf<kqvq!juk<kqbl<!F~zqe<hc< < < < << < < < << < < < < !
“lQg<ogtk<!OkiXolZOliv<!Lgl<!ouTg<Gligqz<!
!Ofig<gqbz<!lvqg<GR<!osie<e!ou{<Gm<mliOl”!
  Skin colour change in to white in colour. 
 
!
4* nEhu!juk<kqb!Oku!vgsqbl<!Fizqe<!hc< < << < << < < !
! !
!! ! -f<Ofijb! G]<mole! %xqEl</! -K! G]<m! ujggtqe<X!
OuXhm<mK! we<hjkBl<! G]<mk<jkh<! Ohiz<! nu<utU! ogiMjlbie! uqbikq!
nz<zoue<Xl<! d{vOu{<Ml</! -f<Ofibqz<! kqm<M! kqm<mig! ou{<jl! fqxlie!
hjmgt<! d{<migq! hqxG! Okgl<! LPuKl<! hvuq! dmjz! uqgivh<hMk<Kkz<!
Lkzqb!G{r<gjt!djmbK/!
!
GxqG{r<gt<!< << << < !
! b,gq!juk<kqb!sqf<kil{q!911!
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6/ gv{!Gm<ml<< << << <!












































! ! ! Fm<hlil<!Hxr<gizqz<!njvbqz<!gi[l<!
! ! kikqbib<k<!kjzke<eqz<!lqGkq!biGl<!
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! ! uizOusq!uqpqbib<!hqk<kk<!kiZKl<!hvkqkiOl/” 
GxqG{r<gt<<< <; 
 Okiz<?!lbqv<!biUl<!squh<H!fqxlib<!gi[l</!







































































































• gibil<! h,! fqxl<! Ohie<x! hjmgt<! svQvolr<Gl<! nmv<f<K! hmv<f<K!
dbv<f<K!gi[l<!
• kqeU!d{<miGl</!













































































Lg<Gx<x!OuXhiMgt<!;< < << < << < < !
! dmZme<! %cb! dbqI! -e<h! Ke<hr<gjt! nEhuqg<gqxK/! nu<uixie<!
nEhur<gTg<G!Kj{!osb<Bl<!gVuqgOt!kk<Kur<gtiGl</!
! leqk!dmzieK!:7!kk<Kur<gjt!nch<hjmbig!ogi{<Mt<tK/!nkqz<!
Lg<Gx<xr<gTl<! ?hR<sh,kr<gTl<! nmr<Gl</! sqk<k! lVk<Ku! Ofib<! fimz<! Ofib<!
Lkeimz<!kqvm<M!F~zqe<!hc!wz<zi!Ofib<gTl<!Lg<Gx<xr<gtqe<!nch<hjmbqz<!
uGg<gh<hMgqe<xe/! weOu! Ofib<! we<hK! ^<K~z! siQvr<gtigqb! sh<k!
kiKg<gTg<Gl<!?utq!?npz<!?Jbl<!Ngqb!Lg<Gx<xr<gTl<!kl<Ljmb!-bx<jg!
ke<jlbqzqVf<K! OuXhMl<! OhiK! d{<migqxK/! sqk<k! lVk<Ku! Ljxh<hc!!
Lg<Gx<xr<gt<!dVuiGl<!uqkl<!hR<sh,k!nch<hjmbqz<!?!
! !!uikl<!! .!! Ngibl< +!uiB!!
!!!!!!!hqk<kl<!! .! OkB!
! !!ghl!< .! hqVkquq+nh<H!
ÄÄuf<kgjz!&e<xqz<!uiB!nhieEme<< < < << < < << < < <!
! Kf<k!hqvi{e<!slieEl<!< < << < << < < .sf<kLxg<< << << <!
%m<MxU!Ovsqk<kiz<!%Xl<!uikl<!hqk<kl<< < < < < < << < < < < < << < < < < < <!
! fim<Mr<!ghOlbil<!fiM}}/< < << < << < < !
uikl<!! .!! -mgjz +!nhiee!
hqk<kl<!! .! hqr<gjz!+ hqvi{e<!
ghl<! ! .! SPLje!+ sliee<!
!! dmx<kiKg<gtqz<! sivl<?! osf<fQi<! hikqh<hjmgqxK/! sivl<! hikqh<hjmf<kui<!
dmx<Osii<Ul<?! leOsii<Ul<?! osf<fQi<! Gjxukiz<! dmz<! fqxl<! GjxkZl<!
d{<migqxK/! sqz! slbl<! OfibieK! De<?! ogiPh<H?! -ux<jx! hikqk<kiz<!
hii<jug<G! nVuVh<Hl<?! uqgivlie! fqxr<gTl<?! Okizqz<! uQg<gLl<?! ouch<Hl<!
d{<miGl<!we!B,gq!%Xgqxii</!
! Ofib<g<G! Lkx<! K~{<Mkzib<! -Vh<hK! Jbg<Gx<xOlbibqEl<?! dmzqz<!
ye<X! ogm! lx<oxie<Xl<! OgmjmuK! -bz<hikziz<! lx<jxb! -v{<M!
Gx<xr<gTl<! Ogm<jmBl<!Lg<Gx<xl<! Ogmjmkjz!okimi<f<K!dmx<! kiKg<gTl<!
ke<!ue<jl!-pf<K!Ofibqe<!GxqG{r<gjt!gim<Ml</!
! lie<!LVg<gqbl<!F~zqz<< < < << < < << < < <!
! ! “uGk<kjz!bcbi!utqLkz<!Le<Xl<!
! ! ! ogMkZx<X!OkiZl<!GVkqBl<!
! ! kjsobe<Hl<!hqxUl<!ogMk<K!











I. uikl<!)<<< Vatham) 





!! k{<jl?! oul<jl! -u<uqv{<miz<! uVl<! yh<Hvuqe<jl! )sVs<sjv*!
we<heuil</!
3/!uiPlqml<<<<!
! nhiee<?! lzl<?! -mgjz?! df<kqbqe<! gQp<&zl<?! gilg<ogic?! -Mh<H!
wZl<H?!Okiz<!fvl<Hg<%m<ml<?!gQz<gt<?!lbqi<g<giz<gt<?!De<?!











! -0K! ye<xibqVh<hqEl<! ke<! -ml<?! okipqz<! Lkzqbux<xiz<! hk<K!
ujgh<hMl<!nju/!
! uikl<<<<! osbz<<<<! ou{<hjmbqz<< << << <!
uikk<kqe<!fqjz< << << < !
2/! hqvi{e<! • &s<Suir<gz<?!&s<SuqMkz<?!
d{ju!osiqg<gs<!osb<kz<!
-bz<H!














































































hqk<kl<< << << <!










! hqr<gjz?! hqvi{uiB?! fQIh<jh?! &zig<gqeq?! -Vkbl<?! kjz?! ogih<H,p<?!
df<kq!-jvh<jh?!uqbi<ju?!fiuqZ~Xgqe<x!fQI?!osf<fQI?!sivl<?!g{<?!Okiz</!












hqk<kl<< << << <! osbz<<<<!
ou{<hjmbqz<< << << <!
hqk<kk<kqe<!< < << < << < < !fqjz!









































 ou{<hjm! Ofibitqgtqz<! nex<hqk<kl<?! -vR<sg! hqk<kl<?! hqvisg! hqk<kl<!
hikqg<gh<hm<mK/ 
III. ghl<<<<!









ogiPh<H! –! ls<js! –! GVkq! .! &g<G.liIH! –! fvl<H! –! wZl<H! .! &jt! –!
ohVr<Gmz<!.!g{<!.!gQz<gt</!
!
4/!-bx<jgh<h{<H< < << < << < < !
! Jbl<!ke<!-bx<jg!fqjzbqz<!fqjzk<kz<!.!ofb<h<H?!gQz<gtqe<!njlh<hqe<!






ou{<hjmbqz<< << << <!


































WP!dmx<kiKg<gt<< < << < << < <!
“okig<G!dkqvk<OkiM!D{<Ljt!fq{l<!we<H< < < < << < < < << < < < < !
!!!!!!Sggqzl<!kiKg<gt<!WP< < << < << < < ” 
                                                       -ytjubii<< <<!
• WP!dmx<kiKg<gTl<!kk<kl<!-bx<jgh<h{<OhiM!-Vf<kize<xq!njugt<!
osb<Bl<!okipqz<!fe<G!fjmohxiK/!




dmx<kiKg<gt<< < << < << < <! h{<H<<< !
ou{<hjmbqz<!< << << <
dmx<kiKg<gtqe<< < << < << < <!<<
fqjz!


















5/!! ogiPh<H! • dXh<HgTg<G!ofb<h<Hh<!hjs!
Dm<c!gcelqe<xq!-bg<Gl<!
-bz<H!



















Ofib<!fqjzbqz<!dmx<kiKg<gTl<!Lk<kiKg<gTl<< < < < < < < << < < < < < < << < < < < < < <;!





!! ghl<! hikqg<gh<hMl<OhiK! ghk<kqe<! %xigqb! l{<{qe<! Hxg<gVuqgtqz<!
we<H?! lilqsl<?! Lc?! fic?! Okiz<! Ngqbjugt<! hikqg<Gl</! ghl<! Oux<Xfqjz!





! gii<h<H! ! .! ! ghk<jk! slh<hMk<Kl<?! uikhqk<kr<gjt! d{<mig<Gl<!
we<hkiZl<! hqk<kg<gizk<kqz<! !Htqh<H?!dui<h<H!Sju!hr<G!ogit<gqxK/!Ggve!
fqjzbqz<! OlZl<! Htqh<H! Sjubqe<! osbz<hiM!d{<m!d{uqe<! l{<h,klieK!
Htqh<H! Sjujb! keg<G! -jvbig! ogi{<M! ogiPh<H! ohiVjt! hikqg<gs<!












!&zikivl<! ! ! Suikqm<miel<!
-vk<kl<! !!!!! ! ! !!!!!





!!!!!!!!!!!!!!hqVkquq!–!)lilqsl<?!Okiz<?!Lc*< << << < !
!
!! ne<elbg<Ogisl<?! hVdmz<! we<hkiz<! WP! dmz<kiKg<gtqz<! sqzUl<!
-f<Ofibqz<! hikqh<hjmBl</! OlZl<! liXhimie! d{UgtiZl<! Okiz<! Ofib<!
Wx<hMl</! -u<uiX! liXhimie! d{Ugtiz<! hqvi{lbOgisl<! we<x! hqvi{e<!
lx<Xl<! ge<Olf<kqiqbl<! hikqg<gh<hMgqxK/! ge<Olf<kqiqbl<! we<hkeiz<! uib<?! jg?!
giz<?! wVuib<?! gVuib<! NgqbjugTl<! hikqg<Gl</! -kqz<! wVuib<! we<hK!
lzk<okimi<hiekiz<! lzg<gqVlqgtiZl<?! gVuib<! we<hK!N{<! oh{<!dbqv[!
we<hkqeiz<!njugjtBl<!hikqg<Gl</!-keiz<!out<jt?!oum<jm!Ofib<gtiZl<!
Okiz<! uqbikq! Wx<hMl</! OlZl<! ole<jlbie! okipqz<Hiqhui<gTg<Gl<! nkqg!
nf<kgv{!osbz<hiM!dt<tui<gTg<Gl<!ou{<Gm<ml<!Wx<hMgqe<xK/!
!
Sju?!Lg<Gx<xl<?!hVugizl<?!-ux<xqx<gie!okimi<H< < < < < < << < < < < < << < < < < < < !
w{<<<<! gizl<<<<! Gx<xl<< << << <!




































































Lg<Gx<xr<gTg<Gl<!hR<sH,kr<gTl<!dt<t!okimi<H< < < < < < < < < << < < < < < < < < << < < < < < < < < < !
! uikl<!! .!utq!+!uq{<!
! hqk<kl<!! .!kQ!
! ghl<! ! .!hqVkquq!+!nh<H!









































w{<ujgk<Oki<U< < << < << < < !
!!!!!!!ÄÄfic! <^hiqsl<!fi!fqxl<!olipq!uqpq!
!!!!!!!lzl<!&k<kqvlqju!lVk<KuviBkl<” 
   ! !!!!!!!!!!!!.OkjvbI!
!!!!!!ÄÄolb<g<Gxq!fqxl<!okieq!uqpq!fi!-Vlz<!!
! ! ! ! ! !!!!jgg<Gxq’ 
                          -ngk<kqbI<<< !
w{<ujg!<<< OkIU!hx<xqb!Gxqh<Hgt< << << < <!
2/fic!
!!!!!!utq?npz<?Jbl<?! gzh<H?! Lg<Gx<xl<! )se<equikl<*! ficgtqe<! ke<fjm?!
Hxfjm!Ngqb!Gxqgjt!nxqbzil</!

























Nk<l!vim<silqIkole<El<!juk<kqb!siv!sr<gqvgl<!< < < < < < << < < < < < << < < < < < < )hg<g!w{<!3:< << << < *!.z<<<<!!

































&k<kqvl<;< << << < !
fQi<g<Gxq;Q < <Q < <Q < < !
“uf<k!fQIg<giq!objm!l{l<!Fjv!wR<soze!
jxf<kqb!Ztju!bjxGK!LjxOb” 
                                                           -sqk<k!lVk<Kuir<gs<!SVg<gl<< < < < < << < < < < << < < < < <!
!! fqxl<!l{l<!wjm!Fjv!wR<sz<!fQIg<Gxq!ofb<g<Gxqjb!hiqOsikqg<gUl</!
Voided urine has the following characters: 
Niram    :  colouration 
Edai       :   specific gravity 
Manam :   smell 
Nurai     :    frothy nature 
Enjal      :  Any deposition seems to the urine. 
           Apart from these, the frequency  of urination,abnormal constituents such as 
protein, blood, pus, renal calculus, crystals etc., also to be found out. 
           In Venpadai  patient, straw or honey  coloured urine is noticed. 
ofb<g<Gxq;< << << < !





                                                               - Okjvbi<<<<!










Oil spreads like a snake  -  vatha neer 
Oil spreads like a ring      -  pitha neer 
Oil kept remaining as such and floating  like a pearl - kaba neer 
Ring in the snake 
Snake in the ring 
Pearl in the snake 
Pearl in the ring 




!! hq{qbxq! Ljxjl! we<hK! dmjzh<! hq{qk<kziz<! Ofijbk<! okiqf<K!
ogit<Tgqx!yPg<gl<!weh<hMl</!















!! lVk<Kue<! ke<je! Ofig<gq! uf<k! hq{qBx<xujeh<! hx<xq! nxqb!
Ou{<cbux<jx! nxqf<Kl<?! ke<ohixq?! Hze<! upqbib<! d{Iujkg<! ogi{<Ml<?!
nue<! yVg<giz<! wg<giv{k<kqeiOzi! Ogm<hjks<!
osiz<Zukx<gqbzikueibqVh<hqe<! nue<! Sx<xik<kijvg<! ogi{<M!
nxqbg<%cbujv!nxqf<Kl<!hq{qbjbg<!g{qk<kjzh<!hx<xqOb!Gxqg<Gl</!



























kQVl<!Q <Q <Q < –!21! ! ! ! ! ! kQvikju!QQQ –!9!!
2/ uqx<Ohimg!Gm<ml<! ! ! ! 2/!H{<mvQg!Gm<ml<!
3/ hil!Gm<ml<! ! ! ! ! 3/!gv{!Gm<ml<!
4/ g\sv<l!Gm<ml<! ! ! ! ! 4/!sqGju!Gm<ml<!
5/ gqV]<{!Gm<ml<! ! ! ! ! 5/!l{<mz!Gm<ml<!
6/ nUKl<hv!Gm<ml<!! ! ! ! 6/!nhvqs!Gm<ml<!
7/ kk<KV!Gm<ml<! ! ! ! ! 7/!uqsv<s<sqg!Gm<ml<!
8/ sqk<Kli!Gm<ml<! ! ! ! ! 8/!uqhikqg!Gm<ml<!















.!B,gq!juk<kqb!sqf<kil{q< << << < !














 sqk<k!lVk<Kul<!sqxh<H!hg<gl<?!38< < < < < << < < < < << < < < < < !
 
2) sqk<kv<!nXju!lVk<Kul<< < < << < < << < < <!F~zqe<!hc<<<  
kQVl<!fqjzQ <Q <Q <  
! lbqv<gjt!ouTg<gh<!h{<{ilZl<!
!!jgbiz<!kmuqz<!OlMht<tlqz<zilZl<<!
! sjmhqe<ez<! Ohiz<! ofVh<hiz<! Sm<mixqb! uMh<Ohiz<! ouTg<gilzqVg<Gl<!
ou{<Gm<ml<!kQVl<!
!
Ofib<g<g{qh<H!uquikl< < << < << < < <;!











!!! uqsi<s<sqg! Gm<mk<kqz<! Okiz<! ouTh<hiGl<! we<X! %xh<hm<cVh<hqEl<!!!!!!!!!!!!
okim<miz<! w{<o{b<! OhizqVk<kz<?! kqeU?! wiqh<H?! Okiz<dXh<H?!!!!!!!!!!!
les<szqh<H?! oum<gqh<H?! Ogihqh<H?! lqgs<squh<H?! kch<H?! ubqx<xqsqU!!!!!!!!!!!!!!!!!!!
Lkzqb!GxqG{r<gjt!ogi{<Mt<te/!









!! -f<Ofibqz<! sVll<! ouTk<K! gi[l<! we<X! %xh<hm<cVh<hqEl<!!!!!!!!!!!
Lkzqz<! squh<hig! um<m{qk<K! hqe<! szju! osb<kK! Ohiz<! ouTg<Gl<!!!!!!!!!!
kqeU{<migq! Ofib<! nkqgiqg<Gl<! lbqi<! SV{<M!dV{<jmbiGl<! ! -kqz<! hqk<k!
ghl<!lqGl<!dmzqz<!nkqglig!kqlqV{<miGl<!dml<H!DKl</!
ouTh<Hmz<;< << << < !
!! hqxg<Gl<OhiOk! dmz<! LPuKl<! fqxlqgtx<X! ouTh<hig! gi[l</!
fqxlqgTme<!%cb!uvl<H!gqjmbiK/!lbqi<gTl<!ouTk<K!gi{h<hMl</!
kQ!H{<{qe<!kPl<H;Q < < <Q < < <Q < < < !
!!!!!kQ! H{<{qx<gie! uvziX! -Vg<Gl<! nu<uqmk<kqz<! ou{<jlfqx! kPl<H!
gi{h<hMl</!
Oklz<;<<< !






ke<uf<kqiq!juk<kqb!F~zqe<hc< < < << < < << < < < !






























ke<uf<kqiq!juk<kqb!F~zqe<hc!kQVl<!kQvi!fqjz< < < < Q < Q< < < < Q < Q< < < < Q < Q !
 lbqi<! ouTk<kz<?! Lke<! Lkz<?! dkM?! dt<tr<jg?! Gkl<?! Gb<bl<?!
-u<uqmr<gtqz<!Okie<xqeiZl<?!Sm<mH{<!Ohie<x!fqxk<Kme<!-Vf<kiZl<?!Ogivlig!
sQg<gqvk<kqz<!hvuqeiZl<!kQviK/!!lbqi<!ouTg<gilZl<?!dmjzg<!jgbiz<!kmu!
OlMht<tl<! -z<zilz<! -Vf<kiZl<! sjmh<hqe<ez<! OhiZl</! ! kQbiz<?! Sm<mixqb!
uMh<OhiZl<?!ouTg<gilZl<!-Vg<gqe<x!ou{<hjm!kQVl</!
! ! ! ! ! ! ! .!B,gq!juk<<<<kqb!sqf<kil{q!<<< .911!
Ofib<!fQg<gl<!)< Q < << Q < << Q < < Line of Treatment*!
gih<H!)<<< Prevention*!
 “ke<uqje!Hxuqje!kipqEl<!lqgqEl<< < << < << < <!
! !dmjzh<<<<hq{qg<G!L{<jlbqK!kiOl< << << < ”!!
!! d{U!lx<Xl<!osbz<gtqz<!lqGkq!nz<zK!Gjxuqe<!giv{lig!dmzqz<!





! ! “liXhi!cz<zik!d{<c!lXk<K{<{q< < < << < < << < < < !
! ! E~Xhi!cz<jz<<< !Bbqi<g<G< << << < ”!
! ! utq?! npz<?! Jbl<! Ngqb! Lg<Gx<xr<gTg<Gl<! liXhicz<zikhc!
d{U!ohiVm<gjt!d{<{!Ofib<!d{<migiK/!
fQg<gl<!)Q < <Q < <Q < < Treatment*!










! ! ! ! ! ! ! ! .skg!fic!
! ki<ll<?! fx<G{l<?! fz<yPg<gl<?! u{g<gl<?! fx<hpg<gl<?! GVhg<kq?!
okb<uhg<kq?!Lkzqbe!h{<ckEg<Gl<?!hq{qbitEg<Gl<!-bx<jgbigOu!-Vg<g!
Ou{<Ml</! h{<cke<! h{<jmb! sqk<ki<! F~z<gjt! fe<G! Nvib<f<K! gx<X?! fe<G!
LcU!ohx<x!lVf<Kgjtk<!kbiiqk<K!nux<jx!hbe<hMk<k!Ou{<Ml</!hq{qbiti<!
ubqk<kqbe<! Olz<! gqVjh! juk<Kl<?! lVf<Kgjts<! siqbig! Wx<Xl<?! hk<kqbl<!
siqbigg<!gik<Kl<?!h{<ckeK!gm<mjth<hc!fmf<K!ogit<t!Ou{<Ml</!
!
hq{q!fQg<gl<!njmukqz<!lVk<Kue<!osb<b!Ou{<cb!gmjlQ < < < < < < <Q < < < < < < <Q < < < < < < < !
!! hq{q!fQg<gl<!njmukqz<!gmUtqe<!gVj{!















! ! ‘uqOvsek<kiz<!uikl<!kiPl< < << < << < < <”!-kx<G!
 fqzuijg!S,v{l<.!4!gqvil<!ouf<fQiqz<!-vU!hMg<Gl<!Le<!
dt<lVf<K;< << << < !
 -zGsQe!S,v{l<!.!½!gqvil<!&e<X!Oujt!ouf<fQiqz<!d{Ug<G!hqe<!












hpg<gupg<gr<gt<< < < << < < << < < < : 
2/ Gtqh<hkx<G! gmjzliU?! hs<jshbX! liU! nz<zK! hqx! &zqjg!
ohiVm<gt<!hbe<hMk<kUl</!
3/ sUg<givl<! ouTg<Gl<! uqjtju! Dg<Guqh<hkiz<! Gtqh<hkx<G!
sUg<givk<kqx<G!hkqzig!fZr<Gliju!hbe<hMk<kzil</!
3. -vh<hi<!osVh<Hgt<!lx<Xl<!jgBjxgjt!kuqi<g<gUl</ (more Benzyle ether 
of hydroquinone present in the slipper gloved are irritate the skin and produce 
depigmenting disorder). 
5/ Ofibitqg<G! Obigise! hbqx<sq! ntqh<hke<! &zl<! le! djts<sjz!
kMg<gzil</!
d{U!Ljxgt<;<<< !












!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!lVk<Ku!keq!himz</< << << < !
!
we<hkiz<!









!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.lVk<Ku!keq!himz<< << << <!
!
we<hkiz<!
!!!!!!hqk<kk<kqe<! kQb! liXkz<gTl<! ghk<kqe<! kQr<Gx<x! lix<xr<gTl<! Gmzqz<!







. lVk<Ku!keq!himz<< << << <!
!




Osi<g<g!Ou{<cb!d{Ugt<< < < << < < << < < <!


















2/ dTf<K! 2/ hisqh<hbX!




















Osi<g<g!%mik!d{U< << << < gt<<<<!


























gmjzujggt<<<<! kqje!ujggt<<<<! kjvgQp<Q <Q <Q <!




















! htqr<ogik<Kg<!gibl<!hVg<gqEl<!hqR<sil<”  .kqVlf<kqvl<< << << <!
!
! gjzfiZ!Ohigqxjk!wm<cx<!OsV!
! ghmlx<x!Okglmi!g{<M!hiOv” ! .gig!Hs{<mi<< << << <!




yVjlh<hMk<kq?! Ohiqe<holie<jxOb! lekqz<! w{<{q! ngk<okipqzqe<!
lik<kqjvbiz<?!Ngl!uqkqh<hc!yPGuK/!
! “-bl!fqblOl!w{<{qzi!Nkel<<< <!
! !!!! fbLX!hqvi{i!bill<hqvk<!kqbigivR<< < << < << < <!
! sblqG!kivj{!kqbieR<!slikq<<< !
! ! nbLXl<!nm<mir<g!liuK!liOl< < << < << < < ”!










! yV! Gxqh<hqm<m! fqjzbqz<! Gxqh<hqm<m! Ofvk<kqx<G! dmjz! fqjzfqXk<kq!
juk<kqVh<hK! Nsel<! weh<hMl</! sqz! Nser<gt<! Gxqh<hqm<m! sqz! Ofib<gjt!
G{lig<Gl</!
 hk<lisel<?! si<uir<gisel<?! suisel<! Okiz<! Ofib<gt<! uvilz<!
kMg<Gl</!
hk<lisel<;< << << < !
! slktk<kqz<! sl<l{lqm<M! dm<gii<f<K! uzK! hikk<jk! -mK! okijm!
lQKl<?!-mK!hikk<jk!uzk<okijm!lQKl<! Wx<xq!-v{<M!jggjtBl<! Ogii<k<K!










si<uir<gisel<;< < << < << < < !
! lz<zif<K!hMk<K?!giz<gjt!olKuig!ym<cbhcOb!OlOz!K~g<gqh<! hqe<!
Hm<mhigk<jkBl<!-Mh<H!higk<jkBl<!OlOz!K~g<gqg<!jggtiz<!LKGh<Hxk<kq<z<!
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Embryology   of the skin : 
  The skin arises from the  two major Embryological elements.Namely called as 
a. Epidermis 
b. Neural crest [ Pigmet cells] 
A.Epidermis: 
  Epidermis begin to develope in the 3rd week of foetal life. Which Originates 
from a surface area of the early gastrula and protect mesoderm tried is brought into 
contact in the inner surface of the epidermis during gastrulation, 
B.Neural crest: 
              The neural crest makes an important contribution to the skin namely called as 
pigment cells. 
Introduction: 
             Vitiligo is a socio – medical problems showing white, non – scaly macules 
endoderm. It is a historical  and  old age disease.                                 
             A first learner of the disease earliest references to the disease can be found in 
Ebrus papyrus( 1550 b.c ). Father of medicine, suhagrat Hippocrates  was the first to 
desire the etiology, classification & treatment of  bars. 
Bars:  synonym of the Disease and it’s Reason: 
    ‘Bars’ is an arabic word which literaly means ‘grazed – out  land” ( a land 
from which grass has been eaten out by cattles, so it appears patchy). In this dieases , 
The colour of skin becomes uneven with patches of  hypo – pigmentation and  
therefore it seems to resemble ‘grazed – out land’. For this reason perhaps. The 
disease has been named as ‘Bars’. 
Paediatric vitiligo: 
Clarity: 
  Vitiligo is an acquired pigmentary disorder of the skin and  mucous membrane 
and  is associate with  loss of melanin and epidermal melanocytes. There is a chronic 
and  progressive loss of melanocytes from the follicular reservoir of  the epidermis. It 
affects 1-2% of the world population, and about 50% of affected patients have an  
onset of disease before the age of 20 years. There are often reports of family 
clustering in children and several susceptibility  loci have been seen is genetic studies. 
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Childhood vitiligo may be quoted as disease occurring with onset before the age of 12 
years. 
Morphology: 
           The morphology of  a vitiligo patch is usually a well defined ivory white 
asymptomatic macule. The distribution of such areas may be local or wide spread 
generalized pattern. The condition has been reported in infants of 4 months Age and  
some reports of congenital disease have been documented. The localized or segmental 
types are common in 4-8 years age group. 
           The ivory white areas are devoid of pigment and are more obvious in dark skin. 
Some lessons are more pronounced after sun  exposure during holidays as the 
surrounding skin normally in contrast to the lesional area . Early spreading areas 
sometimes slow a freckled pattern revealing a typical trichrome pattern. In some 
lessons, a hypopigmented or an inflammatory border may be seen. 
Epidemiology: 
             Vitiligo affects about 1% of the world population, of which 50% starts during 
childhood, causing increased psychological stress during the formative years. The 
estimated prevalence of vitiligo in india is 0.46 – 8.8%.  The prevalence of childhood 
vitiligo ( among patients suffering from this disease) has been reported to be between 
23% and 26%. The prevalence of segmented vitiligo is reported to be higher in 
children (17 – 29%) as  compared to that in adults (5%) (Ref: Vitiligo: A review of 
published work). 
        Available epidemiological data indicate  that in about 25%  patients , vitiligo 
appears before 10 years of age,  mean age at onset of childhood vitiligo in an Indian 
study was 6.2 years. Through rare cases have been reported as early as 6 week after 
birth. A female preponderance has been observed in Indian patients with a male to 
female ratio of 1:1.7. Positive  history of vitiligo in >1 family member has been 
reported in 7-8.5%. 
                          
  
ETIOPATHOGENESIS
     The condition may involve any body site, but broadly may be divided into 
generalized (non-segmental) 
regarding  the pathophysiology of the disease including 
         A. Autoimmune 
         B. neural 
         C. Autotoxic mechanisms 
            In children who are genetically susceptible.
  Autoimmune theory is commonly relevant for generalized vitiligo whereas 
neural hypothsis is more significant for segmental variant.
            The autotoxic mechanism leading to an accumulation of hydrogen peroxide 
due to low catalase activity could be a possib
leading to melanocyte destruc










le factor increasing oxidative stress 









 melanocytes are completely absent in vitiligo lesions as seen on histology.  
Histological stains  like DOPA or Fontana mason can be used to establise the entity.  
In early lesions the melanocytes show vacuolization and granular deposits.  An 
inflammatory  infiltrate  may be seen on histology around  the borders of active 
lesions.  During repigmentation,  there is migration of the cell from the follicular 
reservoir. 
 
Classification of vitiligo: 
TABLE : Classification of Vitiligo 
Segmental Vitiligo Depigmented macules distributed in a dermatomal configuration  
Non segmentalVitiligo Focal Single or few scattered lesions in a nonsegmental 
distribution  
 Vulgaris Extensive lesions in a symmetric fashion 
 Acrofacial Distal extremities and face involved in a symmetric 
fashion 
 Universal Vitiligo involving total or near total body surface 
 Mucosal Lesions limited to mucous membranes  
 
TABLE : Salient features of non-segmental and segmental vitiligo 
 Non-segmental Vitiligo Segmental Vitiligo 
Possible pathogenesis Heritable, Autoimmune Neural 
Autoantibodies Against thyroid gland, gastric parietal 
cell, ANA 
Rare 
Onset Any age Usually in childhood 
Triggering factor Often present Absent 
Evolution Variable, Usually progress with 
appearance of new lesions but can 
remain stationary or even repigment 
A rapid progression 
followed by stabilization; 
if untreated persists 
unaltered there after 
Koebner’s phenomenon May be present Rare 
Halo Nevus May be present Absent 
Associations Autoimmune diseases like thyroidits, 




Addision’s disease  
Therapy Variable response to medical 
treatment, surgical therapy for limited, 
stable vitiligo 
Variable response to 
medical treatment; best 
suited for surgical therapy 
TABLE : CLASSIFICATION OF VITILIGO 
Segmental vitiligo Depigmented macules distributed in a dermatomal  
configuration 
Non segmental vitiligo  Focal                                             Single or few scattered lesions in a 
nonsegmental  distribution 
Vulgaris Extensive lesions in a symmetric fashion 
Acrofacial Distal extremities and face involved in a 
symmetric  fashion 
Universal Vitiligo involving total or near total body 
surface 
Mucosal Lesions limited to mucous membranes 
 
Clinical manifestations: 
                   In  children, common sites are face, peri orbital area, neck followed by 
lower limps, trunk, and the upper extremities. The back is usually spared with some 
involvement of the sacral area. The areas over the chest and abdomen reveal 
widespread pigmentary loss. Perineal and oral involvement in children is also a 
common occurrence. The text is of perineal and oral involvement. Focal involvement 
along the trigeminal segment has been commonly reported in children. 
             Scalp involvement in children can be heralded by early appearance of 
leucotrichia or white hairs within the affected site. Involvement of lips and genital 
vitiligo is relatively common in children, and needs to be differentiated from lichen 
sclerosus at atrophicus when associated with burning and pruritus. Kobner  
phenomenon is more obvious is spreading generalized vitiligo than the segmental 
variety. This phenomenon is more appreciated in children as they are more active and 
playful in nature. The onset of kobner phenomenon signifies active unstable nature of 
the disease. 





1. Vogt – Koyanagi – Marada Syndrome 
2. Alezzandrini Syndrome 
3. APECED Syndrome (Auto immune Polyendocrinopathy Syndrome 1 (APS1) 
or Auto immune polyendocrinopathy candidiasis – ectodermal dystropathy) 
Associated factors; 
                  
 
  
   
 
 
Prognosis and differential diagnosis; 
 In generalized disease    there is a period of rapid spread for few months and  
then it stabilizes for a variable time frame and  otherwise may slowly spread over 
several years.  In comparison to adult disease, regression  and  spontaneous  
repigmentation is mostly diffuse or perifollicular to start with and sometimes from the 
margins.  Segmental variety initially has a period of activity which later on remains 
stable throughout. 
        The condition has to be differentiated from various nevoid conditions like 
nervous depigmentous and anemicus, ash leaf macules and piebaldism. Linear lesions 
of hypomelanosis of Ito, acquired condition  like pityriasis alba and infections like 


















Autoimmune diseases epidemiologically 










                                                How to treat Vitiligo? 













Treatment of Vitiligo 
1. Psychological counselling 
2. Social Counselling 
3. Lasers in Vitiligo 
4. Local Basic fibroblast growth factors in vitiligo 
a. Natural - Placental extract 
b. Synthetic - Melanin 
5. Tacrolimus, Tacravate 
 
Drugs introduced by author in the treatment of vitiligo : 
1. Placental extract in vitiligo acts as a biogenous stimulator.  It stimulates the 
melanocyte to form the melanin acting on the theory of self exhaustion or self 
destruction of melanocytes. 
2. B 665 (Clofazimine) in vitiligo 
3. Geriforte and Liv 52 herbal preparations act as adjunct to psoralen in vitiligo 
4. Pigmento in vitiligo 







 Satisfactory repigmentation can be achieved in up to 70% cases of early.  
Localized disease   Narrow band  ultraviolet B (UVB) or Photochemotherapy  with 
UVA is used extensively either alone or in combination with topical agents as the 
main repigment treatment use of systemic steroids and immunosuppressant or 
immunomodulators in controversial. 
Topical Theory 
 Potent to moderately potent topical corticosteroids can be used for initiation of 
treatment in case of localized, early disease. Repigmentation is generally rapid but 
unstable.   
 Topical pimecrolimus and tacrolimus are found to be effective in vitiligo 
involving head and  neck used either alone or in conjunction with narrow can 
ultraviolet B (NBUVB) or excimer laser. Topical calcipotriol  and tacalcital also  can 
be used  in localized disease either alone on with NBUVB  /PUVA [psoralen 
combined with ultra violet]. 
  Topical  photochemotherapy with topical methoxselen preparations are 
available  and can be used in localized patches and is exposed to UVA or solar 
radiation after 30 to 60 minutes. 
Systemic Therapy: 
                Narrow band UVB therapy is now used extensively In both localized and 
extensive disease. Vitiliginous patches are exposed to 311nm UVB light starting with 
a dose of 0.21 joule/meter square atleast twice weekly on nonconsecutive days till 
minimum erythematic dose is reached. Approximately 50-150 treatments are 
necessary to produce satisfactory response. 
  Photochemotherapy with oral 8-methoxy psoralen or trimethylpsoralen are 
used along with UVA solart radiation to archieve repigmentation. Methoxy psoralen 
is given at a dose of 0.4-0.6 mg/kg/day and vitiliginous patches are exposed to sun for 
15-20 minutes, 2 hours after drug intake thrice weekly on consecutive days. Oral 
photochemotherapy is associated with gastric discomfort and occasional elevation of 
liver enzymes and is slightly less effective than NBUVB theraphy. 
               Pigmentation produced by both NBUVB and PUVA is slow, appears in 




                No specific form of therapy is yet established to control progressive disease. 
Most commonly,  systemic corticosteroids are used in daily immunosuppressive dose, 
but the side effect profile of long-term systemic corticosteroid precludes their regular 
use in children. Modified repigmens of corticosteroids in weekly doses have been 
tried to reduce side effects but their the rapeutic efficacy is not yet established other 
immunosuppressive medication like methotrexate and azathioprine have been tried 
but are not yet established. 
Surgical treatment and its techniques; 
               Long standing vitiliginous patches and these on glabrous skin tend to be 
resistant to treatment and occasionally do not or only partially respond to medical 
treatment .in these circumstances ,surgical transplantation of melanocytes can be 
done to produce pigmentation. Several techniques are used to obtain this result,but 
surgery should only be triedafter carefully assessing stability of the patches. 
Generally, a patch is labeled stable If there is no progression  of the patch or the 
disease for 2 years. But even then test grafting is recommended to as certain. The true 
nature of the disease and to ensure the success of a full procedure. The most 
commonly used surgical techniques are miniature punch grafting, splits 
Thickness skin grafting; suction blister grafting and cultured and noncultured 
melanocyte transplant. 
A. “Miniature punch grafting” is the most commonly practice and  easy  
procedure. In this technique, 1-2 mm sized full Thickness cylindrical 
grafts harvested from nonvitiliginous normal skin and is transplanted pre-
made recipient sites on vitiliginous patches. 
B. “In both split thickness skin grafting” and “suction blister grafting”, 
Thin epidermal sheets are transplanted on derma braded recipient vitiliginous 
patches. The difference is in the process of harvesting the grafts. In one 
dermastome is used while dermoepidermel separation is achieved in the other 
by long-standing suction on the donor sites. 
C. “cultured and non cultured melanocytes transplant produces”The best 
cosmetic result but is difficult and needs laboratory support. In These 
techniques , small amount of normal skin is taken from the donor site and is 
then incubated at 4 c overnight with trypsin solution to achieve cell 
separation. The separated cells and are then either first cultured in appropriate 
media or installed directly in the derma-abraded recipient sites generally 





Table 2: Surgical therapy of vitiligo 
 
Grafting techniques Non-grafting techniques 
 Tissue grafts 
• Minipunch grafting 
• Suction blister epidermal grafting 
• Thin split thickness  grafting 
• Other techniques like ; hair follicle graft, 
smash grafts, mesh grafts, seed grafts, 
and flip top grafts 
• Micropigmentation 
• Excision and closure 
• Dermabrasion 
• Chemabrasion 
• Lasers and lights – excimer 
laser,excimer light,targeted phototherapy  
 Cellular grafts 
• Noncultuerd epidermal cell suspension 
• Noncultured follicular cell suspension 





   Epidermal cell suspensions are being increasingly used in surgical 
management of vitiligo.The technique of noncultured  epidermal suspensions was 
pioneered by gautham et al.They stated that this technique could emerge as a simple 
and effective alternative to the costly cultured melanocyte transplantation 
technique.Olsson and juhlin who pioneered by Swedish procedure of melanocyte 
transplantation first used  the melanocyte medium for  the suspension  of   the  
noncultured  melanocytes . 
Management; 
  The aims of treatment of vitiligo are induction of repigmentation to achieve 
acceptatble cosmetic results and stabilization.  Although there is still no therapeutic 
paracea for vitiligo.  The many options available may lead to satisfactory results in 
most patients.  The efficacy of the treatment depends on duration of the disease, 






 Once the spread of vitiligo is brought under control or the stability of vitiligo 
is achieved, various surgical procedures which can be undertaken are 
micropigmentation or tattooing, punchgrafting, dermabration, split thickness, skin 
grafting melanocyte transfer, etc., one must remember that there is no dietary 
restriction required in such patients.  There is no scientific documentation in favor of 
avoidance of sour food / drink, vit-c or fruit juice, etc.  Lots of reassurance, explaining 





4. MATERIALS AND METHODS 
 
    To find the efficacy of Ilagu Seena Chooranam, the following studies were 
carried out in the present investigation. 
I. Collection, Identification and confirmation of the raw drugs, for the 
preparation of trial drug 
II. Preparation of trial drug 
III. Biochemical analysis of trial drug 
IV. Pharmacological studies of trial drug. 
V. Clinical trial 
          The clinical study on “Venpadai Noi” is being conducted in the out patient 
and in patient postgraduate department of Kuzhanthai Maruthuvam at Government 
Siddha Medical College Palayamkottai and Hospital. 
 
Selection of cases 
 Patients reporting with symptoms of inclusion criteria will be subject to 
screening test and documented using screening proforma. 20 In patients and 20 out 
patients are select. In patients have be given medicine and provided hospital diet. 
Outpatients provided medicine and with dietary regulations. 
 
Inclusion criteria 
• Age 2-12 years.  
• Hypopigmented patch with hyperpigmented border without any structural 
changes in any part of the body 
• Vitiligo present any part of the body 
• Constipation 
• Anorexia  
• Worm infestation.  
• Anemia  
• Children who are willing to undergo investigation and give blood and urine 
sample for laboratory investigation 





EXCLUSION CRITERIA:  
• Total Albinism  
• Dermatological manifestations of leprosy  
• Tinea versicolor  
• Burn scars  
• Dermatological manifestations of addisons diseases  
• Post inflammatory hypopigmentation  
• Pityriasis alba  
• Chemical leucoderma   
 
Withdrawal criteria 
• Occurrence of any adverse reactions 
• Patients turned unwilling to continue in the course of clinical trial 
• Poor patient compliance 
 
Study of clinical diagnosis 
 A case sheet was prepared on the basis of Siddha methodology and modern 
methodology to diagnose the disease. An individual case sheet was maintained for 
each and every patient. 
 A complete history of the patient was taken. Name, Age, Sex, History of 
present and past illness, Antinatal, Neonatal and postnatal history, personal and 
dietaric history, family history and Socio-economic status were noted. 
 Siddha diagnosis was made on the basis of Envagaithervugal, Mukkutram and 
Ezhuudalkattukal. 
 Modern diagnostic methods were adopted with the consultation of pediatric 
professor. 
Tests and assessments 









• Clinical assessment 
To assess the improvement by VASI Score 
 
• Laboratory assessment 
  The Modern diagnostic tests such as blood test for TC, DC, ESR, Hb,  
etc., urine analysis for albumin, sugar, deposits, etc., and stool examination 
for ova, cyst, occult blood to rule out any existing illness. 
 Hemoglobin was estimated before and after therapy. 
 
Administration of Trial Medicine: 
   The trial drug was prepared carefully. 
 Before starting the treatment deworming was done with Nilavagaichoornam – 
3gms Od at night with hot water for 3-5 days. “ Ilagu Seena Chooranam " 1-2gm 
(Honey or water)  after food for 27 days  intake was given to all the 40 patients two 
times a day during their treatment period. 
 The Biochemical analysis of trial drug was carried out in the biochemical 
laboratory and the haematinic effect and Anti Vitiligo action of the drug was tested in 
the pharmacological laboratory. 
 Analysis of observations made from the 20 patients with signs and symptoms 
of the disease were recorded. In addition to  the patients were advised to take iron-rich 
diet and to attend the out patients department for follow up 
Selection of drug and its administration 
 Selection of drug was made after deep study of various siddha literatures and 
finally the drug was selected from Agasthiyar vaithiya pillai tamil. 
 The patients were treated with 
 Bio-chemical analysis of the trial drug was carried out in the department of 
bio-chemistry, GSMC, Palayamkottai.  The details are given in annexure. 
 Pharmacological analysis of trial drug was carried out in the department of 
pharmacology, GSMC, Palayamkottai.  The details are given in annexure. 
Case proforma 
 The symptoms and signs of venpadai history of present and past illness, 
personal history nutritional history, family history, habits, laboratory investigations 





5. DRUG REVIEW 
 
PREPARATIONS OF DISSERTATION MEDICINE: 
-zG!sQe!$v{l<;Q <Q <Q < !
hxr<gqhm<jm! ! ! ! .! 3:/5!gq!
squeii<!Oul<H!Oui<h<hm<jm!! .! 21!gq!
osr<gk<kiiq!Oui<h<hm<jm! ! .! 21!gq!
sr<ge<!Gh<hq!-jz! ! ! .! 21!gq!
Lm<sr<ge<!Oui<h<hm<jm! ! .! 21!gq!
sqXGxqR<sie<!-jz!! ! .! 21!gq!
out<tXG!s&zl<! ! ! .! 21!gq!
giqsijz!s&zl<! ! ! .! 21!gq!
 
PREPARATION: 
  All this drugs individualy purified then  prepare fine powder and then mixed 
together and bottled up. 
Dosage :    ½-1 gm twice a day after food. 
Adjuvant :  Honey (or) water 
Indication :  Venpadai 
Expiry Date : 3 months 





2/hxr<gqh<hm<jm< < << < << < < !
!
Botanical name :  Smilax china 
OuXohbi<<<<! ! ;!! lK^<lQgl<, lK <^lQgq?!sQehm<jm!
Classification: 
Division  :  Angiosperm 
Class       :   Mono cotyledons 
Series      :  Gentianales 
Family     :  Lilliaceae 
Genus    :  Smilax 
Species  :  china 
Organoleptic characters: 
osb<jg<<< ! ! ;!! dmx<Okx<xq,!Olgh<hq{quqzg<gq,!K~b<jlbig<gq!
 








  Root contains fat, sugar, Glucoside, saponin, gum,starch, tannin, 
resin,cinchion along with smilacion and a steroidal saponin yielding on hydrolysis. 
Sarasapogenin have been identified in the tuberous not flavonoid  glycosides and 3 















2.!Lm<<<<sr<ge<!< << << < !
Botanical name :   Azima tetracantha, linn 
OuXohbi<<<<! ! ;!! fx<sr<ge<,!Lm<sr<ge<,!sr<gqjzs<osc!
Classification: 
Class        :   Dicotyledens 
Sub class  :  Gamopetalae 
Series       :   Bicarpellatae 
Other      :   Gentianales 
Family      :   Salvodaraceae 
Genus      :   Azima 
Species    :   Tetracantha 
Organoleptic Characters : 
osb<jg;!<<< !
!!!!!dvlig<gq,!sqXfQi<ohVg<gq!,ouh<hL{<mig<gq,!Ljxouh<hgx<xq!








   Leaves and stem contains 3 diaeric piperidine , Alkaloids , namely Azimine , 
Azacarpine , carpaine , Glutinol , Lupeol , B- sitosterol . 
Sk<kq!;<<< !!
!! K~b!fQiqz<!gPuq!!Olz<Okijz!Sv{<c!wMk<Kg<ogit<tz<!






4/!sr<ge<Gh<hq!-jz< < << < << < < !
Botanical name :   Clerodendron inerme. 
OuXohbi<<<<! ! ;!! sr<ge<Gh<hq,!hQeisr<ge<!Gh<hq,!Lk<kihzl<!
Classification : 
Class      :   Dicotyledons  
Sub class   :   Gamopetalae  
Serios     :   Bicarpellatae  
Order     :   Lamiales 
Family    :   Lamiaceae 
Genus     :   Clerodendron 
Species    :  Inerme 
Organoleptic Character : 
osb<jg!;<<< !
!!!!!dmx<Okx<xq,!dvlig<gq,!ouh<hgx<xq!







Chemical constituents : 
  It is very useful in venereal infection. All types of skin oilment during 
consumtion, Arthritis, insect bite , snake poison , cough with expectoration , all skin 
disease , ascites disorders of blood all these are cured , the leaves  contain an 














Botanical Name  :  Enicostemma Axillare , Blume. 
OuXohbi<!<<< ! ! ;!!!!!NX&zq,!GOzihq,!s{<ml<,!SOukq,!!
hg<Gul<!h{<{q,!kqm<jm,!g{<mizq/!
Classification   :  
Division         :   Angiosperms 
Group             :  Dicotyledons 
Class              :  Bicarpellatae 
Series           :  Gentianales 
Genus             :  Enicostemma 
Species           :  Littorale 
Organoleptic Character : 
osb<jg!;<<< !!
!! hsqk<K~{<c?!dvlig<gq?!dmz<Okx<xq?!fvl<Hvlig<gq/!!








Chemical Constituents : 
             Glycosides , sapnario , ophelic acid , swertisin. 
Sk<kq!;<<< !
!!! s&zk<jk!fe<G!Sk<kl<!osb<K!fQiqz<!gPuq!wMk<Kg<ogit<tz<!








6/!squeii<!Oul<H!< << << < !
!
Botanical Name  :  Indigofera Aspalathoides, linn 
OuX!ohbi<!<<< !! ;!!!!!gif<kiiq,!-jxue<,!squi,!fql<hl<,!!
Lh<Hvoliqk<kie<Oui</!
Classification  : 
Class          :   Dicotyledons 
Sub class    :  Poly petalae 
Series          :  Caliciflorae 
Order         :   Rosales 
Family        :   Fabaceae 
Genus        :   Indigofera 
Species       :  Aspalanthoides 
Organoleptic Characters : 
osb<jg!;<<< !
!!!!!dt<tpzix<xq,!gqVlqokix<xgx<xq,!nPgzgx<xq,!ouh<hL{<mig<gq/!!















7/!sqXGxqR<sie<< << << <!
!
Botanical  Name  :  Gymnema Sylvestre, 
Classification : 
Class            :   Dicotyledons 
Sub class     :   Gamopetalae 
Series           :   Iteteromerae 
Order           :   Ehanales 
Family          :  Asclepidaceae 
Genes          :  Gymnema  
Species        :  sylvestre 
Organoleptic Characters :  
osb<jg!;!<<< !
!!!!!Gtqi<s<sqB{<mig<gq,!dvlig<gq,!hsqk<K~{<c,!Kui<h<hq!








CHEMICAL CONSTITUENTS : 
            Leaves contain genemic and Anthroquinon ,  clalvim oxalate , parabin, 
glucose, carbohydrates. 
            It is hypoglycemic action has been explained on the assumption that the drug 
acts indirectly through stimulation in insulin secretion of the pancreas as it has no 
direct action on the carbohydrate metabolism. 









Botanical Name :  Eclipta prostrata , Linn!
OuXohbi<!<<< ! ! ;! hqVr<gvi\l<,!Okgvi\l<,!jgOssq,!giqh<hie<!
Class    :  Dicotyledons 
Subclass   :   Gamopetalae 
Series    :   Inferae 
Order     :   Asterales 
Family   :   Asteraceae 
Genus    :  Eclipta 
Species   :  prostrata 
Organoleptic Character : 
osb<jg!;<<< !
dmx<Okx<xq,!dvlig<gq,!=vz<Okx<xq,!hqk<kfQi<h<ohVg<gq!







Chemical Constituents : 
               Ecliptine , terthienyl aldehyde , ecliptal , 0.078% nicotine , steroid, 
terpenoid, flavonoids. 











OuXohbi<gt<< << << <!! ! ;! =s<Sv&zq!
Botanical Name   :  Aristolochia  Indica , Linn 
Class                      :  Dicotyledons 
Subclass                : Monoclamideae 
Series                    :   Multiovulatae 
Order                    :  Terrestris 











Chemical Constituents : 
!! Ouiqz<!Aristolochin  we<x!Nz<gzib<Ml<!Allantoin  we<x!gsh<hie<!
GTg<OgijsMl<!fXl{!w{<{<o{Bl<!dt<tK!








:/!osr<gk<kiiq< << << < !
Botanical Name  :  Capparis Seppiaria 
Class                      :  Angiosperms 
Subclass                :  Monocotyledons 
      Order                    :  Brassicales 












Betulin 2- acetate in whole plant x-amyrin, B-amyrin in leaves, B- sitosterol  
botulin. 








Fig. No. 1 INGREDIENTS OF ILAGU SEENA CHOORANAM 
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INGREDIENTS OF ILAGU SEENA CHOORANAM 
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Fig. No. 2 
















6. BIO-CHEMICAL ANALYSIS OF ILAGU SEENA CHOORANAM 
 
Preparation of the extract:   
   5gms of the drug was weighed accurately and placed in a 250 ml clean beaker.  Then 
50ml of distilled water is added and dissolved well.  Then it is boiled well for about 10 
minutes.  It is cooled and filtered in a 100ml volumetric flask and then it is make up to 100ml 
with distilled water.  This fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared extract is taken in 
a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution 




2. TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 





3.  TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 




4. TEST FOR CARBONATE 
The substance is treated with concentrated 
Hcl. 




5. TEST FOR STARCH 
The extract is added with weak iodine 
solution 




6.  TEST FOR FERRIC IRON 
The extract is acidified with Glacial acetic 
acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of Ferric 
iron 
7. TEST OF FERROUS IRON  
The extract is treated with concentrated Nitric 
acid and Ammonium thio cynate solution 





8.  TEST FOR PHOSPHATE 
The extract is treated with ammonium 
Molybdate and concentrated nitric acid 







9.  TEST FOR ALBUMIN 
The extract is treated with Esbatch’s reagent 




10.  TEST FOR TANNIC ACID 
The extract is treated with ferric choloride. 
No Blue black 
precipitate is formed 
Absence of Tannic 
acid 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is added to 
the extract 
It gets decolourised. 
Indicates the 
presence of   
unsaturated 
compound 
12.  TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is taken 
in a test tube and allowed to boil for 2 mins 
and add 8-10 drops of the extract and again 
boil it for 2 mins. 




13.  TEST FOR AMINO ACID 
One or two drops of the extract is placed on a 
filter paper and dried well. After drying, 1% 
Ninhydrin is sprayed over the same and dried 
well. 




14. TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate is 
formed 
Absence of Zinc. 
 
Inference: 
  The extract prepared from the given sample Ilagu seena Chooranam contains, 
sulphate, starch, ferrous iron,  unsaturated compound, reducing sugar,  amino acid 
Biochemical Analysis report was given by Mrs. N.Nagaprema, M.Sc., M.Phil., Head of the 






7. PHARAMACOLOGICAL ANALYSIS 
ANTI – VITILIGO ACTIVITY 
Methods 
Mice 
  C57BL/6 mice at 4 weeks of age were provided by SLRC Laboratory Animal 
(Shanghai, China). B6.129S7-Rag1tmiMomNJU (Rag1 KO) mice at 4 weeks of age 
were bought from Nanjing University Model Animal Resource Information Platform. 
The Rag1tm1Mom mutant strain was developed by Dr. Peter Mombaerts in the 
laboratory of Dr. Susumu Tonegawa at the Center for Cancer Research, 
Massachusetts Institute of Technology. A replacement targeting vector with the Pgk-
neo marker was used. Homologous recombination of the targeting vector resulted in a 
1356 bp deletion in the 5' end of the coding sequence. The C57BL/6J strain was 
generated by backcrossing mice carrying the Rag1tm1Mom mutation 10 times to 
C57BL/6J inbred mice.  
Modeling 
   Female SPF C57BL/6 mice at 4 weeks of age, were divided into four groups,              
5 mice in each group (group – IV)  
Group1 -  The C57BL/6 mice that received Vaseline cream   
Group-II  - C57BL/6 mice that received monobenzone cream  
externaly 
Group-II  - IC57BL/6 mice that received monobenzone cream &  
low dose of drug 
Group-IV - C57BL/6 mice that received monobenzone cream &  
high dose of drug on the 2×2 cm shaved area . Creams 
were completely massaged in using a spatula. 
Depigmentation evaluation 
  The extent of depigmentation was objectively quantified by an observer 
blinded to the treatment groups. Each exposure location was examined, and the extent 
of depigmentation was estimated as a percentage of the anatomic site. Points were 
awarded according to the following scheme: no evidence of depigmentation (0%), 0; 
>5%, 1 point; >5–25%, 2 points; >25–50%, 3 points; >50–75%, 4 points; and 75–
100%, 5 points. The depigmentation score was defined as the sum of the scores. The 
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vitiligo score of an experimental group was reported as the mean individual score of 
the mice within that group. 
MONOBENZONE SCORE 
Table - 1 
 
S.NO DEPIGMENTATION SCORE POINT 
GROUP I 0 
GROUP II 4.5 
GROUP III 3.2 








GROUP I 0% 
GROUP II 75% 
GROUP III 50% 












GROUP I GROUP II GROUP III GROUP IV
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Fig. No. 4 
A  B  
C  D  
 
 
  Figure 1. depigmentation induced by monobenzone in mice. (a the c57bl/6 
mice that received vaseline cream did not show depigmentation (a) the c57bl/6 mice 
that received monobenzone cream developed depigmentation on the monobenzone-
exposed site (b) distant depigmentation developed at low dose . (c) distant 





 Experimental Methodology 
   Animal belongs to group I received normal saline 5ml/kg. Group II rats were 
treated with Phenyl hydrazine (PHZ) 40mg/kg (i.p) for two days (Day1 and Day2) 
and were served as disease control. Animal belongs to group III received PHZ 
injection 40mg/kg (i.p) and treated with 200 mg/kg ISC  from 3rd to 16th Day. 
Whereas animal belongs to group IV treated with 400 mg/kg ISC from 3rd to 16th 
Day and served as Treatment group. 
 
Blood Collection 
  At the end of the study, before sacrifice, the animals were fasted for overnight 
with free access to water. Animals were sacrificed with excess anesthesia. Blood 
samples were collected from Retro-Orbital Sinus puncture and stored in EDTA 
(ethylenediamine - tetra acetate) test tubes for Haematological analysis. Bone Marrow 
of Control and Treatment group animals were collected using Fine Needle Aspiration 
Technique for further processing. 
 
Bio-chemical Parameter 
  At the end of the study blood will be collected by ocular puncture after 
overnight fasting animals. The blood parameters such as Red Blood Cell Count 
(RBC), White Blood Cell Count (WBC), 
  Haemoglobin Concentration (Hb) and Haematocrit was determined using 
Mindray BC 2800 Haematology Analyzer . 
 
 Statistical analysis 
 Results are presented as the average ± Standard deviation and the differences 
among Test groups were assessed by one- way analysis of variance followed by 
Dunnett’s multiple comparison test using Grapad prism 5.0 software (Graph pad, La 





Table – 2 
Haematology Profile of Phenyl hydrazine induced Anaemic rats 
Group Treatment 
RBC WBC HGB 
HCT (%) 




7.41 ± 0.02 8.02±0.1 12.80±0.2 38.4±0.4 
II 
Phenylhydrazine (PHZ) 
40 mg / kg ,i.p 
4.81±0.01 6.04±0.2 6.93±0.02 20.79±0.01 
III PHZ+ ISC 200mg/kg, p.o 5.6± 0.20 7.62±0.1 8.04±0.01 24.12±0.04 
























(PHZ) 40 mg / kg 
,i.p
PHZ+ ISC  
200mg/kg, p.o
PHZ+ ISC  
400mg/kg, p.o
I II III IV
RBC (×10 6µl)





Table - 3 
Group Treatment MCV(%) MCH(pg) MCHC 





II Phenylhydrazine (PHZ) 40 mg / kg ,i.p 43.22±1.90 14.40±0.45 25.12±2.24 




































EFFECT OF ISC ON HAEMATOLOGY PROFILE OF PHENYL 
HYDRAZINE INDUCED ANAEMIC RATS 
 
  The Mean Haemoglobin (Hb) content (g/dl) of rats belongs to disease Control 
group was decreased significantly 6.93±0.02 when compare to that of the Saline 
control group 12.80±0.02, which signifies the induction of Anaemia in Experimental 
animals. There was significant increase in Hb content were observed in animals 
treated with 200 and 400mg/kg of ISC with 8.04±0.01 and 10.74±0.2 respectively. This 
observation reflects the promising Haematinic property of the trial drug ISC in treated 
rats. 
             There was a significant decrease in the level of RBC(×10 6µl) were observed 
in animals belongs to group II 4.81±0.01when compare to that of the normal control 
rats with 7.62± 0.1. Treatment with ISC at both the dose level shown marked increase 
in RBC level with 5.6± 0.20for ISC 200mg/kg and 6±9.1for ISC 400mg/kg. Similar 
results were observed with respect to WBC count. 
            The Haematocrit (HCT) test indicates the percentage of od by volume that is 
composed of red blood cells. Treatment with PHZ shown significant decrease in HCT 
with the level of 17±0.01 lower when compare to control rats with HCT 43±0.4. 
Animals treated with 200 and 400mg/kg of ISC has shown increased HCT value of 
26.02±0.04and 30.34±0.84respectively. 
            Iron deficiency anaemia is a common disease affecting women especially in 
reproductive age. It is characterised by microcystic hypochromic RBC, in which PCV 
,MCV and MCH are reduced. It occurs due to defective haemoglobin 
  The haematological parameters such as PCV,MCV,MCH and Hb are 







1. Hye Won Lee. Hemopoietic effect of extracts from constituent herbal 
medicines of Samultang 
1. on phenylhydrazine-induced hemolyticanemia in rats. Int J ClinExpPathol. 
2014; 7: 6179–6185. 
2. Aboudoulatif D. Effect of Tectonagrandis on phenylhydrazine-induced 
anaemia in rats.Fitoterapia.2008; 79:332–336. 
3. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small 
laboratory animals. J PharmacolPharmacother. 2010;1:87–93. 
4. Verley H. Practical Clinical Biochemistry.New Delhi: CBS Publishers. 2003. 
5. Proudlock RJ, Statham J, Howard W.Evaluation of the rat bone marrow and 
peripheral blood micronucleus test using monocrotaline. Mutat Res. 
1997;392:243-249. 
6. Snykers S, Vanhaecke T, Rogiers V. Isolation of rat bone marrow stem cells. 
Methods Mol 
7. Biol. 2006; 320:265-272. 
8. Karimi M, Mirzaei M, Dehghani A. Prevalence of anemia, iron deficiency and 
iron deficiency anemia in 6-60 month old children 
9. in Yazd's rural area. Int Pediatr. 2004; 19:180–184. 
10. 8. Berger J, Dillon JC. Control of iron deficiency in developing countries. 
Sante.2002; 12: 22– 30. 
11. 9. Yip R, Ramakrishnan U. Experiences and challenges in developing 
countries. J Nutr.2002; 132: 827–830. 
12. 10. Matthew J. Anemia, Iron Deficiency. Stat Pearls Publishing. 2017. 
13. 28. Wang M. Iron Deficiency and Other Types of Anemia in Infants and 





EVALUATION OF ACUTE TOXICITY STUDY OF  
Effect of Acute Toxicity Study (14 Days) of ILAGU SEENA CHOORANAM 
Table no –4   Physical and behavioral examinations. 
Group 
no. 
Dose(mg/kg) Observation sign No. of animal  
affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
































Body position Normal 3 3 3 3 3 








Normal 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 
Approach 
response Normal 3 3 3 3 3 
Touch 
response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch 
response Normal 3 3 3 3 3 
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Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral 
closure Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary 
reflex Normal 3 3 3 3 3 3 
Abdominal 
tone Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
 
Table no-7   Mortality 
 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
RESULT: 
  From acute toxicity study it was observed that the administration of ILAGU 
SEENA CHOORANAM at a dose of 2000 mg/kg to the rats do not produce drug-
related toxicity and mortality. So No-Observed-Adverse-Effect- Level (NOAEL) of 





  ILAGU SEENA CHOORANAMwas administered single time at the dose 
of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed 
for consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behavioural signs of any toxicity due 
to administration of ILAGU SEENA CHOORANAM at the doses of 5mg/kg, 
50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
ILAGU SEENA CHOORANAM on the growth rate. Body weight change in drug 




 ILAGU SEENA CHOORANAMwas administered single time at the dose 
of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed 
for consecutive 14 days after administration. Doses were selected based on the pilot 
study and literature review. All animals were observed daily once for any abnormal 
clinical signs. Weekly body weight and food consumption were recorded. No 
mortality was observed during the entire period of the study. Data obtained in this 
study indicated no significance physical and behaviou ral signs of any toxicity due 
to administration of ILAGU SEENA CHOORANAM at the doses of 5mg/kg, 
50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
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  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups.Food consumption of all treated animals was found normal as 
compared to normalgroup. 
  Body weight at weekly interval was measured to find out the effect of 
ILAGU SEENA CHOORANAM on the growth rate. Body weight change in drug 




SUB-ACUTE TOXICITY STUDY IN WISTAR RATS TO EVALUATE 
TOXICITY PROFILE OF ILAGU SEENA CHOORANAM 
Table :8 EFFECT OF SUB- ACUTE DOSE (28 DAYS)OF ILAGU SEENA 
CHOORANAM ON BODY WEIGHT IN GRAM 
GROUP CONTROL LOW  MID HIGH 
1st day 126.3±1.03 130±1.543 128.3±2.231 130.3±2.23 
7th day 136.3±1.03 135.3±1.343 135±2.113 141±2.11 
14th day 140.1±1.004 106.3±1.12 106.4±2.012 107.4±2.012 
21st day 107.3±2.120 116.2±1.501 108±1.131 109±1.13 
28th day 117.3±1.041 116.3±1.202 147±2.0405 150±2.040 
 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 






















EFFECT OF SUBACUTE DOSE (28 DAYS)OF ILAGU SEENA 
CHOORANAM 
Table : 9  ERU KARA PARPAM ON ORGAN WEIGHT (PHYSICAL 
PARAMETER) IN GRAM 
GROUP CONTROL LOW  MID HIGH 
HEART 0.47±0.02 0.28±0.04 1.05±0.11 0.45±0.02 
LIVER 2.35± 0.23 2.37±0.23 2.24±0.01 2.27± 0.23 
LUNGS 1.35±0.10 0.35±0.14 0.54±0.24 1.47±0.10 
KIDNEY L 0.47±0.02 1.56±0.03 0.47±0.02 0.45±0.02 
 R 0.45±0.024 1.19±0.02 0.45±0.024 0.46±0.024 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 



















EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF ILAGU SEENA 
CHOORANAM ON HAEMATOLOGICAL PARAMETERS 















































































Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one 
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 





























































































Table :11  EFFECT OF SUB- ACUTE DOSE(28 DAYS)OF ILAGU SEENA 














Control 42.18±3.02 13.28±4.31 243.16±11.32 35.39±3.00 0.78±0.03 
LOW 42.17±3.22 11.27±4.01 251.15±12.42 40.57±2.42 0.54±0.04 
MID 40.25±4.44 12.35±2.21 245.49±4.14 39.16±2.22 0.69±0.04 



































































EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF ILAGU SEENA 
CHOORANAM BIOCHEMICAL PARAMETERS 
Table - 12 








0.808±0.2457 0.78±0.2827 0.818±0.76 0.74±0.19 
  
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 

















EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF ILAGU SEENA 
CHOORANAM ON FOOD INTAKE IN GRAM 
Table – 13 
 






1st DAY 18.37±13.5110 19.1676±14.3 12.14±21.71 17.9±7.62 
7th DAY 15.9±11. 10.867±12.67 16.77±9.853 11.21±14.41 
14th DAY 18.87±8.72 10.87±14.28 14±13.96 19.76±8.981 
21st DAY 11.91±12.4 15.4±8.466 15.92±9.43 19.21±8.02 
28th DAY 12.14±11.38 18.42±11.50 10.4±8.90 10.4±7.57 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 



















Table:14. EFFECT OF SUB- ACUTE DOSE (28 DAYS) OF  ILAGU SEENA 
CHOORANAM ON WATER INTAKE IN ML 





1st DAY 98.3338±13.5110 89.1672±14.3426 102.10±21.7199 67.5±7.6203 
7th DAY 85.5±11.7938 100.863±12.6770 76.6673±9.85363 81.6717±14.4150 
14th DAY 58.3383±8.72817 90.8363±14.2812 80±13.9692 89.1672±8.88981 
21st DAY 91.6687±12.4949 85±8.46662 65.8338±9.43550 89.1717±8.79602 
28th DAY 82.10±11.3840 88.3348±11.5004 80±8.90061 70±7.57773 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); nsp>0.05, *p<0.05, **p<0.01, 




















Table: 15  EFFECT OF SUB ACUTE DOSES (28 DAY) OF ILAGU SEENA 
CHOORANAM ON ELECTROLYTES: - 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dunnett’s(n=6); NS- non-significant, *p<0.05, 













CONTROL ISC(200mg/kg) ISC (400mg/kg) ISC (600mg/kg)
SODIUM






Sodium (mg/dl) 144.10±0.6855 134.30±0.6792 111±0.7571 121.80±0.70 
Calcium(mg/dl) 6.0±0.89 3.20±0.13*** 4.7±099*** 6.180±0.1*** 
Phosphorus 
(U/L) 































 All animals in this study were free of toxic clinical signs throughout the dosing   
period of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout the 
dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals from control and different dose 
groups exhibited comparable body weight gain throughout the dosing period of 28 
days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food consumed by 
animals from different dose groups was found to be comparable with that by control 
animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in Table 
No.22 Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations conducted on day 29 revealed following 
significant changes in the values of different parameters investigated when compared 
with those of respective controls; however, the increase or decrease in the values 
obtained was within normal biological and laboratory limits or the effect was not dose 
dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on the day 29th and recorded in 
Table no 24, 25 revealed the following significant changes in the values of hepatic 
serum enzymes studied. When compared with those of respective control. However, 







1) All the animals from control and all the treated dose groups up to 
2000mg/kg survived throughout the dosing period of 28 days. 
2) No signs of toxicity were observed in animals from different dose groups 
during the dosing period of 28 days. 
3) Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be 
comparable throughout the dosing period of 28 days 
5) Haematological analysis conducted at the end of the dosing period on day 
29th, revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29th, 
no abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was 








8. ANTIMICROBIAL STUDIES 
Aim 
 To study the Anti-microbial action of “Ilagu Seena Chooranam” 
against  Streptococcus pneumoniae and Staphylococcus aureus. 
 
Medium 
Mueller Hinton agar. 
 
Components of medium  
Beef extract   - 300gms/lit 
Agar    - 17 gms/lit 
Starch    - 1.5 gms/lit 
Casein Hydroxylate  - 17.5 gms/lit 
Distilled water  - 1000 ml 
PH    - 7.6 
 
Procedure 
 The media was prepared from the above components and poured and 
dried on a petri dish. The organism was streaked on the medium and the test 
drug (1gm drug in 250ml of water) was placed on the medium. This is 
incubated at 37°C for one over night and observed for the susceptibility shown 
up clearance around the drug. 
 
Result: 
  The test drug Ilagu Seena Chooranam was sensitive against 













9. OBSERVATIONS AND RESULTS  
 
Results were observed with respect to the following criteria: 
1. Age reference 
2. Sex reference 
3. Religion 
4. Socio-economic status of the patients 
5. Aetiology 
6. Diet reference 
7. Seasonal reference 
8. Distribution of thinai 
9. Mode of onset 
Reference to mukkuttram 
10. Vatham reference 
11. Pitham reference 
12. Kabam reference 
13. Ezhu Udalkattugal 
14. Envagai thervugal 
15. Neerkuri, neikuri reference 
16. Particulars of in patients 
17. Site of lesion 
18. Investigation before and after treatment. 
19. Vasi score – OP record 
20. Vasi score – IP record 












Table No. 1   AGE REFERENCE 
 
S.No. Age Number of cases 
(Out of 40) 
Percentage (%) 
1 1-5 years 4 10 
2 5-6 years 4 10 






 The percentage was highest in the age group of 6 – 12 years, the 






























Table No. 2. SEX REFERENCE 
 
S.No. Sex Number of cases 
(Out of 40) 
Percentage (%) 
1 Male Children 20 50 


































Table No. 3. RELIGION REFERENCE 
 
S.No. Religion Number of cases 
(Out of 40) 
Percentage (%) 
1. Hindu 24 60 
2. Christian 5 12.5 









































 Out of 40 patients, 47.5% of cases were Lower,  30% of cases were 



























S.No. Socio economic status 
Number of cases 
(Out of 40) Percentage (%) 
1 Lower income groups 19 47.5 
2 Middle income groups 12 30 




Table No. 5. ETIOLOGY REFERENCE   
 
S.No. Etiology 
Number of cases 
(Out of 40) 
Percentage (%) 
1 Contact Allergens 3 7.5 
2 Positive family history 1 2.5 
3 Others (Diet, Climate, 






  Out of 40 patients Contact allergens was seen in 7.5% of cases, Positive 

































































S.No. Diet habit Number of cases 
(Out of 40) 
Percentage (%) 
1 Vegetarian 5 12.5 
2 Mixed diet 35 87.5 
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Table No. 7. PARUVAKAALAM 
S.No. Paruvakaalam Number of cases 
(Out of 40) 
Percentage (%) 
1. Kaarkaalam (Aavani & Puratasi) 3 7.5 
2. Koothirkaalam (Ayppasi & Karthigai) 2 5 
3. Munpanikaalam (Markazhi & Thai) 5 12.5 
4. Pinpanikaalam (Maasi & Panguni) 15 37.5 
5. Elavenilkaalam (Chithirai & Vaikaasi) 11 27.5 





 According to Paruvakaalam high incidence of 37.5% of cases in Pinpani 
kaalam,  27.5% of cases in Elavenil Kaalam, 12.5% cases in Munpanikaalam, 












































































Number of cases 
(Out of 40) 
Percentage 
1 Kurinji (Hill) 2 5 
2 Mullai (Forest) - - 
3 Marutham (Fertile) 36 90 
4 Neithal (Coastal) 2 5 


































S.No. Mode of onset Number of cases 
(Out of 40) 
Percentage (%) 
1 Acute 25 62.5 


















































  In Dasa Vayu, Abanan was affected in 8  patients (20%), Viyanan 























































 In pitham prasagam was affected in 40 patients (100%), Analaga 



















































In Kabam, klethagam was affected in 14 patients (35%). 
Avalambagam was affected in 40 patients (100%) Tharpagam, Pothagam, 



























UDAL KATTUGAL REFERENCE 
































All 40 patients were affected saaram and senneer was affected in 































a) Vatha pitham  
b) Pitha vatham 

































Naadi was affected in 40 patients a) Vatha pitham was affected in 
27 patients (67.5%), Pitha vatham was affected in 9 cases (22.5%), Pitha 
kabam was affected in 4 patients  (10%)  and niram were affected all of 
the 40 in-patients (100%), vizhi was affected in 14 patients (35%), malam 




















































































NEERKURI AND NEIKURI REFERENCE 







1.  Spreading like snake 
2.  Spreading like ring 


















  Neerkuri was observed in 40 patients (100%) 
 
Inference : 
  In neikuri was affected in Vatha Neer present in  27 patient (67.5%), Pitha 

















































SITE OF LESION 














Both upper and Lower limb 
























































































































 Table No. 17  OUT PATIENT RECORD  
S.No  Op.No.  Name  Age /Sex  No. of  days treated  Remarks  
1.  21898  Irbana  11FC  30 days  Moderate  
2.  22325  Nandha kumar  11MC  29 days  Good  
3.  22651  Sharmila devi  7FC  30 days  Good  
4.  28844  Divya prakash  7MC  44 days  Moderate  
5.  29726  Vijay balaji  11MC  28 days  Good  
6.  30220  Aara adhithya  4MC  45 days  Good  
7.  31312  Seyad thaslima  10FC  48 days  Good  
8.  36929  Maria saroja  12FC  46 days  Moderate  
9.  40733  Hasina  8FC  32 days  Good  
10.  42943  Amna  9FC  46 days  Moderate  
11.  42901  Aslam  5MC  26 days  Good  
12.  52340  Ulaganathan  2MC  31 days  Good  
13.  52591  Shrimathi  9FC  29 days  Good  
14.  52947  Kamanutheen  6MC  29 days  Good  
15.  59006  Shankar  8MC  30 days  Good  
16.  72890  Kayalvizhi  9FC  23 days  Moderate  
17.  23743  Selvaraj  12MC  28 days  Good  
18.  23744  Shrimathi gayathri  9FC  34 days  Mild  
19.  39334  Jaisan  9MC    28 days  Good  




Table No.  INPATIENTS CASE SHEET REPORTS  















1.  1412  Muthulingam  12MC  6 Months  Hypopigmented patches present in the both legs and 
both hands and face without itching ,loss of appetite 
present  
28.05.2018  25.06.2018  27  Moderate  
2.  2335  Meenakshi  3FC  4 Months  Hypopigmented patches present in the both legs and 
right fingers  without itching 
14.09.2018  
  
09.10.2018  25  Good  
3.  2543  Rishwana  12FC  3 Months  Hypopigmented patches present in the right index 
finger  without itching, constipation present 
09.10.2018  24.10.2018  16  Mild  
4.  2948  Malathi  12FC  2 Months  Hypopigmented patches around the face  without 
itching, constipation present 
03.12.2018  31.12.2018  28  Good  
5.  2951  Joshlin  7FC  1½  
Months  
Hypopigmented patches present in the left elbow 
joint  without itching 
03.12.2018  25.12.2018  22  Good  
6.  3132  Sherina  8FC  1 Year   Hypopigmented patches around the scalp without 
itching , loss of appetite present. 
22.12.2018  22.01.2019  30  Moderate  
7.  3183  Lakshmana 
kumar  
12MC  2 Months  Hypopigmented patches present in the wrist joint and 
left index and middle fingers without itching 
28.12.2018  23.01.2019  27  Good  
8.  270  Kumar  11MC  15 days  Hypopigmented patches present in the left middle 
finger  without itching, constipation present 
06.02.2019  04.03.2019  27  Good  
9.  291  Prema varshana  9FC  3 Months   Hypopigmented patches present in the both legs 
without itching, constipation present 
08.02.2019  08.03.2019  29  Moderate  
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10.  305  Hariharan  10MC  3 Months  Hypopigmented patches around the face  without 
itching, loss of appetite present 
09.02.2019  07.03.2019  27  Mild  
11.  383  Mohamed  11MC  1 Month  Hypopigmented patches present in the back of the 
region without itching 
16.02.2019  17.03.2019  30  Good  
12.  564  Venkatesh  12MC  2 Months  Hypopigmented patches around the face, both knee 
joint, left hand and lower lip without itching, 
constipation present 
 05.03.2019  02.04.2019  31  Moderate  
13.  691  Rishwana 
begam  
12FC  2 weeks  Hypopigmented patches present in the right index 
finger without itching,loss of appetite present 
18.03.2019  14.04.2019  28  Good  
14.  822  Abdul azeem  4MC  1½  months  Hypopigmented patches around the scalp region and 
the face without itching, loss of appetite present 
30.03.2019  25.04.2019  27  Moderate  
15.  828  Mercy  8FC  2 Months  Hypopigmented patches around the scalp,behind the 
right ear  without itching,loss of apprtite present 
30.03.2019  25.04.2019  27  Moderate  
16.  893  Prema  5FC  1 Month  Hypopigmented patches present in the cheeks and 
right upper and lower eyelids without itching , 
constipation present 
06.04.2019  03.05.2019  28  Good  
17.  946  Ramkumar  12MC  2 Months   Hypopigmented patches present in the right middle 
finger and right index finger without itching,loss of 
appetite present  
15.04.2019  13.05.2019  29  Good  
18.  950  Shrimathi  10FC  3 Months  Hypopigmented patches present in the chest region 
and right elbow joint  without itching, constipation 
present 
15.04.2019  13.05.2019  29  Mild  
19.  944  Bharath shri  5MC  1 Month  Hypopigmented patches present in the right knee 
joint and right elbow joint  without itching ,loss of 
apprtite present 
15.04.2019  13.05.2019  29  Good  
20.  1017  Aprose  12FC  20 days  Hypopigmented patches around the face  without 
itching, constipation present 




Table No. 19. LABORATORY INVESTIGATIONS  
S.No.  OP.No  Name of the patient  
Haematological Investigation  Urine Analysis  Motion Analysis  
WBC Total  
Count cells /  
cu.mm  
WBC differential count  ESR – mm/ Hr  
Hb gm%  
Before Treatment  After Treatment  Before Treatment  
After 
Treatment  
BT  AT  BT  AT  
A  S  D  A  S  D  Ova  Cyst  Ova  Cyst  
BT  AT  P%  L%  E%  P%  L%  E%  
½ 
hr  1hr  
½ 
hr  1hr  BT  AT  
1   21898 Irbana 9000  9200  62  30  8  64  30  6  5  10  4  8  11  11  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
2  22325 Nandhakumar 9600  9800  54  44  2  54  45  1  7  14  6  12  9  11  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
3   22651 Sharmila devi 8200  9600  55  35  10  57  37  6  6  12  5  10  12.1  12.6  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
4  28844  Dhivya Prakash 7800  8600  47  44  9  48  44  8  5  10  4  8  12  12  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
5   29726 Vijay balaji 10000  10050  54  39  7  55  40  5  7  14  4  8  9  10  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
6  30220  Aara adhithya 8600  8700  65  30  5  66  30  4  6  12  5  9  9.1  10.5  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
7   31312 Seyad thaslima 8300  8400  59  36  5  60  35  5  8  16  6  15  10  10  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
8   36929  Mariya saroja 11200  11400  66  28  6  66  39  5  6  12  5  10  11.2  11.4  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
9   40733 Hasina 8800  9000  48  44  8  49  44  7  7  14  4  8  12.1  13  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
10  42943 Amna 9500  9600  60  32  8  60  34  6  6  12  4  8  9.9  10.4  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
11  42901  Aslam 8300  8500  60  35  5  61  35  4  5  10  3  7  9  10  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
12  52340 Ulaganathan 8700  9200  56  37  7  57  39  4  6  12  5  10  9.8  8.7  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
13  52591 Srimathi 9650  9750  68  26  6  68  29  3  6  12  4  9  8.9  9  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
14  52947 Kamalutheen 9400  9600  64  30  6  65  31  4  7  15  5  10  11.5  12  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
15  59006 Shankar 8300  8500  52  40  8  53  42  5  5  10  4  8  10.5  11.2  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
16  72890  Kayalvizhi 8800  9000  56  34  10  59  35  6  8  16  7  14  11  12  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
17  23743 Selvaraj 9200  9500  60  26  14  60  30  10  9  18  5  10  9.2  11.5  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
18  23744 Srimathi Gayathri 9800  9900  59  35  6  62  35  3  7  14  6  12  11.5  11.7  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  
19   39334 Jaisan 7950  8050  68  26  6  68  28  4  8  16  7  14  10.5  10  Nil  Nil  NAD  Nil  Nil  NAD  Nil  Nil  Nil  Nil  




Table No. 20. LABORATORY INVESTIGATIONS  
BT – Before Treatment,   AT -  After Treatment, P – Polymorphs,  L – Lymphocytes, E-Eosionophils,   ESR – Erythrocyte Sedimentation Rate, Hb - 
Haemoglobin A- Albumin, S – Sugar, D – Deposits,N - Nil 
S.No. IP.No Name of the patient 
 Haematological Investigation Urine Analysis Motion Analysis 
WBC Total 
Count cells /  cu.mm 
 WBC differential count ESR – mm/ Hr 
Hb gm% 
Before Treatment After Treatment Before Treatment After Treatment 
 BT AT BT AT 
A S D A S D Ova Cyst Ova Cyst 
BT AT P% L% E% P% L% E% ½ hr 1hr 
½ 
hr 1hr BT AT 
1 1412 Muthulingam 10000 10050 54 39 7 55 40 5 7 14 4 8 9 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2 2335 Meenakshi 7800 8600 47 44 9 48 44 8 5 10 4 8 12 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3 2543 Rishwana begam 8200 9600 55 35 10 57 37 6 6 12 5 10 12.1 12.6 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4 2948 Malathy 9600 9800 54 44 2 54 45 1 7 14 6 12 11.9 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5 2951 Joshlin 9000 9200 62 30 8 64 30 6 5 10 4 8 11 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6 3132 Sherina 9500 9600 60 32 8 60 34 6 6 12 4 8 9.9 10.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7 3183 Lakshmana kumar 8800 9000 48 44 8 49 44 7 7 14 4 8 12.1 13 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8 270 Kumar 11200 11400 66 28 6 66 39 5 6 12 5 10 11.2 11.4 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9 291 Prema varshana 8300 8400 59 36 5 60 35 5 8 16 6 15 10 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10 305 Hariharan 8600 8700 65 30 5 66 30 4 6 12 5 9 9.1 10.5 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11 383 Mohamed 8300 8500 52 40 8 53 42 5 5 10 4 8 10.5 11.2 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12 564 Venkatesh 9400 9600 64 30 6 65 31 4 7 15 5 10 11.5 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13 691 Rishwana 9650 9750 68 26 6 68 29 3 6 12 4 9 8.9 9 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14 822 Abdhul azeem 8700 9200 56 37 7 57 39 4 6 12 5 10 7.8 8.7 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15 828 Mercy 8300 8500 60 35 5 61 35 4 5 10 3 7 9 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16 893 Prema 9750 9800 61 30 9 62 31 7 6 12 5 10 10 11.5 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17 946 Ramkumar 7950 8050 68 26 6 68 29 4 8 16 7 9.5 9.5 10 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18 950 Srimathi 9800 9900 59 35 6 62 35 3 7 14 6 11.5 11.5 11.7 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19 944 Barathsri 9200 9500 60 26 14 60 30 10 9 18 5 9.2 9.2 10.5 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
20 1017 Aprose 8800 9000 56 34 10 59 35 6 8 16 7 11 11 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
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DISTRIBUTION ACCORDING TO THE CLINICAL PRESENTATION 
VASI SCORE: VITILIGO AREA SEVERITY INDEX (VASI) 
 
  Its name is an adoption from PASI SCORE in Psoriasis. The percentage of 
vitiligo involvement is calculated in terms of hand units. One hand unit is 
approximately equivalent to 1% of the total body surface area. The degree of 
pigmentation is estimated to the nearest of one of the following percentages. 
  100% - Complete Depigmentation, No pigment is present 
 90% - Specks of pigment present 
 75% - Depigmented area exceeds the pigmented area 
 50% - Pigmented and Depigmented areas are equal 
 25% - Pigmented area exeeds Depigmented area 
 10% - Only specks of Depigmentation present 
  The vasi for each body region is determined by the product of the area of 
Vitiligo in Hand units and the extend of Depigmentation within each hand unit 
measured patch 





Table – 21 
OUT PATIENT RECORD 
 
S.No Op.No. Name Age /Sex 
VASI SCORE Clinical 
improvement Before treatment 
After 
treatment 
1. 21898 Irbana 11FC 0.45 0.22 Pigmented spots 
present 
2. 22325 Nandha kumar 11MC 0.37 0.18 Good 
improvement 
3. 22651 Sharmila devi 7FC 0.37 0.12 Good 
improvement 
4. 28844 Divya prakash 7MC 0.75 0.37 Pigmented spots 
present 
5. 29726 Vijay balaji 11MC 0.25 0.12 Good 
improvement 
6. 30220 Aara adhithya 4MC 3.75 1.87 Good 
improvement 
7. 31312 Seyad thaslima 10FC 0.37 0.09 Good 
improvement 
8. 36929 Maria saroja 12FC 2.4 1.2 Pigmented spots 
present 
9. 40733 Hasina 8FC 2.4 1.2 Good 
improvement 
10. 42943 Amna 9FC 0.37 0.18 Pigmented spots 
present 
11. 42901 Aslam 5MC 1.87 0.93 Good 
improvement 
12. 52340 Ulaganathan 2MC 0.37 0.09 Good 
improvement 
13. 52591 Shrimathi 9FC 3.6 1.8 Good 
improvement 
14. 52947 Kamanutheen 6MC 0.25 0.12 Good 
improvement 
15. 59006 Shankar 8MC 0.9 0.45 Good 
improvement 
16. 72890 Kayalvizhi 9FC 0.37 0.28 Pigmented spots 
present 
17. 23743 Selvaraj 12MC 2.4 1.2 Good 
improvement 
18. 23744 Shrimathi gayathri 9FC 2.4 1.9 Mild 
pingmentation 
present 
19. 39334 Jaisan 9MC   0.75 0.37 Good 
improvement 





















































Table – 22 
IN PATIENT RECORD 
 
S.No Ip.No. Name Age /Sex 
VASI SCORE Clinical 
improvement Before treatment 
After 
treatment 
1. 1412 Muthulingam 12MC 4.2 2.1 Pigmented spots present 
2. 2335 Meenachi 3FC 1.5 0.75 Good improvement 
3. 2543 Rishwana 12FC 0.9 
 
4.45 Mild pingmentation present 
4. 2948 Malathi 12FC 0.1 0.05 Good improvement 
5. 2951 Joshlin 7FC 0.38 0.19 Good improvement 
6. 3132 Sherina 8FC 0.9 0.85 Pigmented spots present 
7. 3183 Lakshmanakumar 12MC 3.38 1.69 Good improvement 
8. 270 Kumar 11MC 0.45 0.45 Good improvement 
9. 291 Prema varshana 9FC 0.38 0.29 Pigmented spots present 
10. 305 Hariharan 10MC 0.1 0.05 Mild pingmentation present 
11. 383 Mohamed 11MC 0.25 0.12 Good 
12. 564 Venkatesh 12MC 6.8 4.4 Pigmented spots present 
13. 691 Rishwana begam 12FC 0.37 0.18 Good improvement 
14. 822 Abdul azeem 4MC 3.3 1.95 Pigmented spots present 
15. 828 Mercy 8FC 1.5 0.95 Pigmented spots present 
16. 893 Prema 5FC 3 1.5 Good improvement 
17. 946 Ramkumar 12MC 1.5 0.75 Good improvement 
18. 950 Shrimathi 10FC 2.7 1.85 Mild pingmentation present 
19. 944 Bharath shri 5MC 0.75 0.37 Good improvement 














VASI SCORE GRAPH 
 
 
















































IP. No. 291          Name : Premavarshana          Age : 9 /FC 
       
            BEFORE TREATMENT  AFTER TREATMENT 
OP. No. 28844          Name : Divyaprakash        Age : 7 /MC 
        
BEFORE TREATMENT   AFTER TREATMENT 
IP. No. 822          Name : Abdulazeen         Age : 4 /MC 
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BEFORE TREATMENT   AFTER TREATMENT 
IP. No. 564          Name : Venkatesh         Age : 12 /MC 
        




Table – 23 
 RESULTS ACCORDING TO AGE CRITERIA AFTER TREATMENT 
S.No Age 
Good Relief Moderate Relief Mild Relief 
Number 
of 







Cases              











1. 1 – 5 Years 3 7.5 1 2.5 - - 










 Among 40 cases, the Good Relief percentage was highest in the age group of   
6 – 12 years, the percentage was 45%, 5 – 6 years the percentage was 10% and 
between the age group of 1 - 5 years, the percentage was  7.5% 
  The Moderate Relief percentage was highest in the age group of 6-12 years, 
the percentage was 25% and between the age group of 1-5 years, the percentage was 
2.5% 
  The Mild Relief percentage was highest in the age group of both 6-12 years 




















Good Relief Moderate Relief Mild Relief





    
Table – 24 
 
RESULTS AFTER TREATMENT  
  
S.No.  Mode of onset  Number of cases  
(Out of 40)  
Percentage (%)  
1  Good  25  62.5 % 
2  Moderate  11  27.5 % 
3.  Mild  4  10 % 
     
Inference:  
   Out of 40 patients cases 62.5% of cases showed significant improvement,  































    Venpadai is one of the eighteen types of kuttam described by saint yugi muni 
resembles in its clinical features that of “vitiligo” in modern medicine. In siddha 
literature,  it is an acquired depigmented condition of the skin characterised by the 
appearance of the milky white patches on the skin are described as the main clinical 
feature, these coincide with vitiligo.  
   Anatomy and physiology of skin and aetiology, clinical features are discussed 
in many siddha literatures .  Authour collected these largely from, yugi vaidhya 
chinthamani, siddha maruthuvam sirappu, thanvanthri vaidhyam, pothu maruthuvam 
and aruvai maruthuvam.  
   20 cases were selected for treatement according to the clinical features 
mentioned in siddha maruthuvam sirappu, siddha methods of diagnosis was carried 
out.  During the course of treatment the patient subjected to the following  routine 
investigation.  
1. In blood TC, DC, ESR and Hemoglobin percentage, blood urea, serum 
cholesterol,  
2. In urine, albumin, sugar and deposit.  
3. In stools ova, cyst.  
4. Size and shape of the lesion, colour of the skin, colour of the hair in the 
affected region and photography were takan before treatment and after 
treatment.  
5. Eventhough depigmentation is present in other disorder like diabetes mellitus, 
leprosy,  thyrotoxicosis were excluded 
Incidence according to Age Distriibution:  
   In the present study both in the outpatient ward and inpatient ward the 80% 
cases were found in the age group 6-12 years 10% of patients were found in 5-6 years 
and 10% of cases were found age group in 1-5 years 
Incidence according to to Sex Distribution:  
        40 patients of both sexes were selected for the dissertation study.  Among the 
40 cases50% were male children and 50% were female children.   
Incidence according to Religion: 
      Among 40 patients , 24 (60%) patients are Hindu, 5 (12.5%) patients are 
Christian, 11(27.5%) patients are Muslim. 
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Incidence according to Socio – Economic status:  
   47.5% of patients were from poor socio-economic status , 30% from middle 
class family and 22.5% from high income group.  Nutritional defects also one of the 
cause of venpadai.    
Incidence according to Etiology : 
     Out of 40 patients,  
  3 patients  ( 7.5%) were affected by contact Allergens 
   1 patient (2.5%) were affected bt familial predisposition 
  36 patients (90%) were affected by others (Diet, climate, Debility) and 
Unknown. 
Incidence according  to  Diet :   
    Only 12.5% of patients treated were vegetarian and the rest 87.5% were found 
to be taking mixed diet. 
Incidence according  to Paruvakaalam:  
   37.5% were affected in pinpani kaalam (Masi – Panguni) 
           27.5% were affected in elevenil kaalam (Chithirai – Vaigasi) 
         12.5% were affected in munpani kaalam (Margzhli – Thai) 
           10% were affected in Muthuvenilkaalam (Aani & Aadi) 
          7.5% were affected in kaarkalam ( Aavani & purattasi ) 
         5% were affected in koothir kaalam (Ayppasi – Karthigai)  
Incidence according to Thinai:  
   90% of patients were belonging to maruthanilam.  In siddha literature reveal 
that maruthanilam is as place that can be regarded as “disease free zone” and cures all 
the disease.  But various environmental chages in the life style in marutham, disease 
venpadai occurs irrespective of any place.  Maximum patients came from in and 
around Tirunelveli which belongs to maruthanilam.  
  5% of patients were belonging to neithal nilam 
  5% of patients were belonging to kurinji nilam.  
Incidence according to Mode of Onset: 
     Out of the 40 patients, 25 (62.5%) cases affected by acute onset  and  15 




Incidence according to Mukkutram:  
VATHAM:  
• Viyanan and Samanan were affected in 100% of cases.  
• Abanan was affected in 20% of cases.  
• In Venpadai helminthes, amoebiasis, digestive upset and  nutritional defects 
also one of the cause leads to digestive problem, loss of appetite, constipation.  
PITHAM:  
• Prasagam was affected in 100%, it gives complexion to the skin.  
• In Venpadai skin colour changes in due to prasagam affected.  
• Anarpitham was affected in 35% of cases.  It gives appetite and helps for 
digestion.  Digestive upset is one of the cause of Venpadai  And also Ranjagam 
was affected in 35% of cases.  It gives colour to the blood.   
• Decreased haemoglobin percentage is one of the cause of Venpadai.  
KABAM:  
• Klethagam 35% of cases were affected.  
• Klethagam helps in digestion.  
• In Venpadai digestion problem is common due to helminthes, amoebiasis and 
nutritional disorder.  
• Avalambagam 100% of cases were affected 
Incidence according to Udal Kattugal:  
• Saaram was affected in 35% of cases.  
• Seneer was affected in 35% of cases.  
• Saram is responsible for skin colour.  
• Senneer is responsible for complexion of the skin.  In Venpadai Saram and 
senneer were affected for all cases.  
Incidence according to Envagai Thervugal :  
   In Envagai thervugal Niram was affected in 100% of cases, because in 
Venpadai skin colour change into white.  
  Vizhi affected in 35% of cases.  
  Naadi 67.5% of patients had the higher incidence of vatha pitham, 22.5% of 
patients had the incidence of pitha vatham and the remaining 10% of patients had 




Incidence according  to neerkuri and neikkuri:  
   In Neerkuri 100% of the patients had straw coloured urine.  In neikuri process 
the oil resembled that of spreading like a snake 67.5% , 22.5% spreading like a ring 
and spreading like a pearl 10% 
Incidence according to Results  After Treatment: 
          Out of 40 patients 25(62.5%) have good relief, 11 patients (27.5%) have 
Moderate relief and remaining 4 patients (10%) have Mild relief. 
MANAGEMENT:  
   In siddha system the treatment is based on the deranged dhosa.  The vatha, 
pitha and kaba dhosa are brought down by Viresanam, Vamanam and Anjanam 
respectively.  
  Initially 3 gm of Nilavaagai choornam was give with hot water of bed time 
after food .  
Drug:  
Internal  
   Ilagu seena  chooranam  - 1/2-1 grams twice a day(Morning and Evening) with 
honey or water after food.  
Good Relief:  
• White patches are completely reduced.(Evidence of photos or enclosed)    
• No new lesion has developed.  
Moderate Relief:  
• White patches moderately reduced   
• No new lesions developed   
• Black colour pigmentation formed in affected area.  
• Other symptom are well reduced satisfactorily.  
Mild Relief:  
• White patches were slowly reduced   
• Partially new pigmentation are formed  
• No new lesion developed in other parts of body  
• Diet restriction was instructed to the patient during the course of treatment.  
• During discharge the patients were advised to follow yogasanas and 
pranayamam.   These helped them to prevent recurrences and patients felt 
better in doing them.  
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• Pharmacological studies were carried out in the Department of pharmacology 
Government Siddha Medical College, Palayamkottai.   
• Chemical analysis of the drug was also done in department of biochemistry 
laboratory  of Government Siddha Medical College,  
• Palayamkottai.  
• All the drugs were put to therapeutic only after careful purification process laid 
down for them individually.  
• No toxic or side effects were clinically and reported observed in any case 








   The dissertation work on Venpadai is choosen by author and with an intention 
to give physically and mentally also clinical relief to the patients those who are 
suffering from this disease, with out any harm.  
   Various literature have been collected regarding venpadai from siddha texts as 
well as modern  text books.  
   Venpadai noi is a disease affecting both male and female children as per the 
Siddha and Modern systems of Medicine. 
   To treat children with Vitiligo, a Siddha trial drug, “Ilagu seena chooranam" 
has been prepared. The collection, confirmation, and purification of all ingredients 
have been described. The method of preparation of “Ilagu seena chooranam” has 
also been described. 
           The biochemical analysis of the trail drug shows the presence of Sulphate, 
Starch, Ferrous iron, Unsaturated Compound and Reducing Sugar the results 
have been tabulated. The pharmacological effects such as Haematinic, Anti Vitiligo 
activity  of trail drug have been studied and the results have been tabulated. 
   The trail drug, Ilagu seena chooranam has been used to treat 20 inpatients of 
children  both sexes affected by Venpadai  IPD ward of PG- KuzhanthaiMaruthuvam 
Department of GSMC. Maximum occurance of this disease was observed in children(2 
to 12years). 
    Before treatment, the signs and symptoms for Venpadai are noticed and 
confirmed by clinical analysis. During treatment, the dose of ½-1 g of Ilagu seena 
chooranam,twice a day after meals, has been given to  children . 
  Findings reveal about the impact of the disease in the body. Statistical study of 
the details in the case sheet was observed and the results have a see through idea about 
the disease. 
   No adverse side effects were reported during or after the course of treatment. 
          The bio-chemical analysis and pharmacological study of the drug revealed its 
efficacy. From the studies, the drug Ilagu seena chooranam possesses significant 
Haematinic and Anti vitiligo action. 
        By analyzing and taking into consideration of all these results, it is inferred that 








 The clinical study  shows that 62.5% of patients were cured and 11 cases had 
moderate relief and 4 cases had mild relief.  
 The trial drugs were very effective to the patients and there was no recurrence 
of symptoms.  
 Cost of the drug is very cheap and free from side effect.  So they are useful for 
long term purposes.   
 The trial medicine were very safe to the children.  
 The drugs along with yoga and pranayama as supportive therapy showed very 
good prognosis.  
 The drug is a herbal product , easily available, easy to administrate, simple way 
of  preparation, high efficacy, harmless to infants and children 
 The dose of the drug used in present study is to be used in pediatric practice to 





1. Textbook of  Paediatric Dermatology 
2. Pigmentary Disorders for Children 
3. Colour Atlas and Synopsis of  Pediatric Dermatology  
4. Care of the New Born 
5. Achar’s Text book of Pediatrics 
6. Roxburgh’s Common Skin Diseases 
7. Rational  skin therapy and dermatological drugs 
8. Illustrated Textbook of  Dermatology 
9. Agathiar Kanma Kandam 
10. Anubava Vaidhya deva ragasiam 
11. Agathiyar Vaidhyam 
12. Agathiyar Guna Vagada thirattu 
13. Bio-chemistry – U. Satyanarayana, U. Chakrapani 
14. Chigitcha Ratna Deepam Vaithya Chinthamani- Kannusamy Pillai 3rd edition. 
15. Common skin diseases - Rox burgh’s 15th edition. 
16. Common disorders of Pigmentation -3rd edition- Davidson’s Principles and 
practice of medicine. 
17. Dhanvanthri vaithyam 
18. Heritage of the Tamil –siddha medicine 
19. Guna Padam mooligai – murugesa mudaliar 1969 
20. Guru Naadi -235 
21. Indian material medica vol l & ll – Nadkarni A.K. 
22. Man Murugiam – Kavi rasa panditha rama subramania navalar 
23. New text book of psychiatry- Lin ford Dees 1988. 
24. Anuboga vaithiya murai part 3 - Dr. C.N. Kuppusami and Dr. V.S. Parvathy 
25. Pathartha Guna vilakkam - Moola Vargam - C. Kannuusamipillai 
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31. Pathologic basic of disease – Robbinson 
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32. Principles of Nutrition & Dietetics 
33. Practice of dermatology 6th edition BehI.P.N. 
34. Sambasivan Pillai T.V. 1938 Tamil – English Medical Dictionary 
35. Sattamuni Gnanam 
36. Siddha maruthuvanga surukam 
37. Skin and venereal diseases – K. Skriphin 
38. Siddha maruthuvam Sirappu – Thiagarajan 1986 
39. Siddha maruthuvam Pothu – Kuppusamy Mudaliyar K.N.-1954 
40. Siddha Aruvai maruthuvam – Uthamarayan 
41. Thirumoolar thiru mandiram 
42. Tamilar Thai Maruthuvam 
43. The wealth of India 
44. Thirumoolar Karukkadai vaidhyam – 1924 
45. Yoogi Vaidhya chinthamani – Peru nool 800 vo.I. 































































GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “VENPADAI”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS ILAGU SEENA CHOORANAM 
Form I-SCREENING & SELECTION PROFORMA 
     S.I.No: ………….  OP/IP No: ……….  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:…………. Reliability :  …………… 
INCLUSION  CRETERIA:     YES      NO   
• Age 2-12 years.       
• Hypopoigmented patch with hyperpigeted border 
without any structural changes in any part of the body 
• Vitiligo present any part of the body 
• Constipation 
• Anorexia  
• Worm infestation.  
• Anemia  
EXCLUSION CRITERIA:  
• Total Albinism  
• Dermatological manifestations of leprosy  
• Tinea versicolor  
• Burn scars  
• Dermatological manifestations of addisons diseases  
• Post inflammatory hypopigmentation  
• Pityriasis alba  
• Chemical leucoderma   
 
 
Signature of Guide:         Signature of Principal Investigator:  
 



































GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY ON “VENPADAI”. A PEADIATRIC 
DISORDER AND THE DRUG OF CHOICE IS ILAGU SEENA CHOORANAM 
 
FORM IA – HISTORY PROFORMA ON ENROLLMENT 
 
Patient id: OP/IP NO. VISIT DATE (___/____/_____) 
NAME :  
AGE:  
Gender:   MALE           FEMALE  Date Of Birth :( ____/____/_____)   
Fathers/Mother/Guardian name :  
Fathers Occupation:  
Fathers Monthly income:  
Religion:  
Socioeconomic status:  



















2. Present illness  
 
History of past Illness 
History /Symptoms /Signs   Yes  No  if, Yes Details  
Any Similar Complaints      _____________ 
Bronchial Asthma       _____________ 
Dust Allergy        _____________ 
Hospitalization        _____________ 
Any Other         _____________ 
 
Family History       
Any hereditary familial Disease    Yes  No 
If yes, details………………………………………………………………………….. 
 
Immunization History  
Proper Immunization given   Yes  No …………………….. 
 
Food Habits:  
1. Veg   2. Non-Veg   3. Mixed  
 
General assessment                            Yes  No 
1. Picca 
2. Nail Biting 
3. Bowel Movements  
 
General Examination   Yes  No   
1. Pallor       
2. Jaundice        
3. Cyanosis         
4. Clubbing         
5. Pedal oedema        






















1. Pulse rate / mint 
2. Heart rate / mint 









Mid Arm Circumference 
 
CLINICAL EXAMINATION: 
             Normal            Affected 
 Cardio Vascular system:        
 Gastro intestinal system:        
 Musculo skeletal system:        
 Central nervous system:        
 Endocrine system:  
 





2. Colour: Normal    Reddish      Black    Pallor    
3. Itching: No                     Mild                 Moderate            Severe                   
 
EXAMINATION OF NAILS: 
1. Pallor:  Present              Absent               







    







            Kurinji  Mullai                Marutham        Neithal         Paalai 
KaalaIyalbu 
Kaarkalam  Koothirkaalam Munpanikaalam 
Pinpanikaalam Illavenikaalam Muthuvenrkaalam 
Yaakai 
Vatham  VathaPitham  VathaKabam 
Pitham   PithaVatham  PithaKabam 
Kabam   KabaVatham  KabaPitham 
UyirThathukkal 
Vatham 






























































































Niram     













































Niram  Normal   Affected 
Edai  Normal   Affected 
Nurai  Normal   Affected 
Manam Normal   Affected 









 Vadham  Pitham   Kabam 
 
ThonthaNadi 




Admitted to trial : 1. Yes   2. No. 






Date :      
Signature of the Guide   Signature of Principal Investigator: 
 





















GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
BRANCH IV – KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI - 627 002. 









           
         
       












Bed. No. : 
 











PG-Pediatric Ward, Government Siddha 

















Date of Admission: 
 
 

































Consanguinity    : 
 Ataxia     : 
 Blindness    : 
 CP     : 
 MR     : 
 Seizure    : 
 Movement disorder   : 





 Bowel and micturation habit  : 
 Sleep     : 
 Enuresis    : 
 Thumb sucking   : 
 Nail biting    : 
 Pica     : 
xxiv 
 
Diet History : 
 Appetite    : 
 Types of diet    : 
 
Antenatal History : 
 Medication    : 
 Infection (STARCH)   : 
 Irradiation    : 
 Toxaemia    : 
 Hemorrhage    :  
 Severe Anaemia   : 
 Eclampsia    : 
 H/o Decreased foetal Movements : 
 Maternal malnutrition   : 
 Maternal Diabetes Mellitus(DM) : 
 Maternal Hypertension  : 
 
Natal: 
 Breech presentation   : 
 Forceps / - C- Section   : 
 Home / Hospital   : 
 H/o prolonged labour   : 
 
Post Natal 
 Post partumHaemorrhage  : 






 Birth Weight    : 
 Term / Pre term baby   : 
 Congenital malformations  : 
 Birth Asphyxia – APGAR – Score : 
 Neonatal convulsions   : 
 Kernicterus    : 
 Diarrhoea    : 
 Birth injury / Head injury / Activity of the child 
a) at birth   : 
b) after birth   : 
Time of cry after birth  : 
Resusscitation done or not  : 
(if done nature of resusscitation) 
Respiratory distress / cyanosis : 
Fever / altered sensorium  : 
Feeding after birth   : 
Lymphadenopathy   : 
 
Developmental History : 
 
 





 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 





1. Consciousness : 
2. Decubitus  : 
3. Anemia   : 
4. Jaundice   : 
5. Cyanosis   : 
6. Clubbing   : 
7. Pedal oedema  : 
8. Lymphadenopathy   : 
9. Nourishment  : 
10. Skin changes   : 
11. Edema   : 
12.JVP   : 
13.Pulse Rate   : 
14.Heart Rate   : 
15.Respiratory Rate  : 
16.Temperature  : 
17.Blood Pressure  : 
18.Spine   : 
19.Skin    : 
 
Systemic Examination 
Cardio Vascular System : 
Respiratory System  : 
Gastro Intestinal System : 
Genito Urinary System : 
Nervous System  : 
 Consciousness: 
 Temper Tantrum:  Sociable- Irritable - Playful 
 Memory  : 
 Orientation  : 
 Speech   : 
 Intelligence (I.Q) : 




Cranial Nerve Examination: 
Motor System: 
 Power  : 
 Tone  : 
 Reflex  : 
 Grip  : 
 Gait  : 
 
Sensory Examination: 
 Superficial Sensation: 
  Touch  : 
  Pain  : 
  Temperature : 
 Deep Sensation: 
  Position sense : 
  Joint sense : 
  Vibration sense: 
 Cortical Sensation: 







Siddha Systems – Clinical Examination: 
Nilam 
Kurinchi  : 
Mullai   : 
Marutham  : 
Neithal   : 





Kaar   : 
Koothir  : 
Munpani  : 
Pinpani   : 
Elavenil  : 




Praanan  : 
Abaanan : 
Uthaanan  : 
Viyaanan  : 
Samaanan : 
Naagan  : 
Koorman : 
Kirugaran  : 
Devathathan : 
Dhananjeyan  : 
 
Pitham 
Analam  : 
Ranjagam  : 
Sathagam  : 
Alosagam  : 
Prasagam  : 
 
Kabam 
Avalambagam  : 
Kilethagam   : 
Pothagam   : 
Tharpagam   : 




Saaram    : 
Senneer   : 
Oon     : 
Kozhuppu   : 
Enbu     : 
Moolai    : 
Sukkilam/Suronitham  : 
EnvagaiThervugal 
Naadi    : 
Sparisam   : 
Naa    : 
Niram    : 
Mozhi    : 
Vizhi    : 
Malam    : 
Moothiram   : 
Neerkuri 
Niram    : 
Manam   : 
Nurai    : 
Edai    : 






Nirami   : 
Nurai    : 
Elagal   : 







TC  : 
DC : 
Hb  : 
ESR  : 
2. Urine 
Albumin  : 
Sugar   : 
Deposits  : 
3. Motion 
Ova   : 
Cyst  : 
Occult blood  : 
DIFFERNTIAL DIAGNOSIS  : 
PROGNOSIS    : 
MARUTHUVAMURAI   : 
ADVICE     : 






   
   
   
   
   
   
   
   




GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY ON “VENPADAI”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS ILAGU SEENA CHOORANAM 
FORM - II&IIA 
CLINICAL ASSESMENT ON ENROLLMENT DURING AND AFTER TRIAL 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: ………… 
Date of Completion :………….   Informant: …………. Reliability :  …………… 
SIDDHA SYSTEM OF EXAMINATION 
 I.ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 





















7.MALAM: [BOWEL HABITS / STOOLS] 
 





























Constipation Present/ Absent Present/ Absent Present/ Absent Present/ Absent 





NEERKURI 1st Day 9th Day 18th Day 27th  Day 
Niram White/ White/ White/ White/ 
[Colour] Yellowish/ Yellowish/ Yellowish/ Yellowish/ 
 Straw Straw Straw Straw 
 coloured/ coloured/ Coloured/ coloured/ 
 Crystal Crystal Crystal Crystal 





















































II.THEGI: [TYPE OF BODY CONSTITUTION] 
 
III.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
 
Kurinji Mullai  Marutham NeithalPalai 
    (Hillyterrain)      (Forestrange)         (Plains)           (Coastalbelt)  (Aridregions) 
IV.KAALAM: 
Kaarkalam  -   Pinpanikalam   - 
Koothirkalam  -   Ilavenil  - 
Munpanikalam -   Muthuvenil  - 
V.MUKKUTRAM:[AFFECTION OF THREE HUMORS]  
A)VATHAM: 
 1st  Day 9th Day 18th Day 27th  Day 
Praanan     
Abaanan     
Viyaanan     
Udhaanan     
Samanan     
Naagan(Higher intellectual 
function) 
    
Koorman(airway of yawning)     
NEIKURI 1st Day 9th Day 18th Day 27th  Day 
Serpentine fashion     
Annular/Ringed  fashion     
Pearl beaded fashion     




Kirukaran(Air of salivation/nasal  
secrection) 
    
Devathathan (Air of laziness)     
Dhananjeyan(this air that acts 
on death) 
    
B.PITHAM: 
 
 1st  Day 9th Day 18th Day 27th  Day 
Analpitham (Gastric juice)     
Ranjagam(Haemoglobin)     
Saathagam(Life energy)     
Praasagam (Bile)     
Aalosagam     
 
C.KABAM: 
 1st  9th Day 18th 27th  Day 
Avalambagam (Serum)     
Kilaethagam (saliva)     
Pothagam (lymph)     
Tharpagam(cerebrospinal 
fluid) 
    
Santhigam(synovialfluid)     
 
VI.SEVEN DHATHUS: (7 SOMATIC COMPONENTS) 
 1st  Day 9th Day 18th Day 27th  Day 
Saaram [Chyme]     
Senneer [Blood]     
Oon [Muscle]     
Kozhuppu [Fat]     
xxxv 
 
Enbu [Bones]     
Moolai [Bonemarrow]     
Suronitham[Genital  discharges]     
 1.SYSTEMIC EXAMINATION: 
 
 1st  9th Day 18th 27th  Day 
1)Gastrointestinal  System     
2) Respiratory System     
3)Cardiovascular  System     
4)Central Nervous System     
5)Urogenital System     
 
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
 
2. GENERAL EXAMINATION: 
 1st 5th 9th 12th 15th 20th 27th 
Height (cms)        
Weight (kg)        
Temperature (F0)        
Pulse rate (per min)        
Heart rate (per min)        
Respiratory rate(per min)        
Blood pressure (mm/Hg)        
Anaemia        
Jaundice        
Cyanosis        
Lymph adenopathy        
Pedal edema        
Clubbing        












    
Constipation 
    
Loss of appetite 
    
Worm Infestation 
    
Anemia 







Signature of the Investigator: 
 
Signature of the Guide : 
 
 
    




GOVERNMENT SIDDHA MEDICAL 
COLLEGE&HOSPITALPALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF 
KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “VENPADAI”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS ILAGU SEENA CHOORANAM 
 
S.I.No: ………….  OP/IP No: …………  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:…………. Reliability :  …………… 
 
FORM III – LABORATORY INVESTIGATION 
 






Hb (gms%)    11.5- 14.5   
T.RBC (milli/cu.mm) 4-4.9   
ESR(mm) ½ hr. 0-4   
1hr. 0-13   
T.RBC (milli/cu.mm) 5000-14500   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
 
 
Urine Investigation Before TMT  
Date : 
After TMT  
Date : 
Albumin   
Sugar   





Stools Investigation Before TMT  
Date : 
After TMT  
Date : 
OVA   
Cyst   
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GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 





An open clinical study to evaluate the safety and efficacy of Siddha sasthric 
formulation“ILAGU SEENA CHOORANAM”for the management “VENPADAI” 
CERTIFICATE BY INVESTIGATOR 
I certify that I have disclosed all the details about the study in the terms 
readily understood by the parent. 
Date ……………….      Signature………….. 
place ……………….     Name ……………… 
CONSENT OF INFORMANT 
  I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up 
including the laboratory investigations to be performed to monitor and safeguardmy 
Son / Daughter body functions. 
  I am aware of my right to opt out of the trial at any time during the courseofthe 
trial without having to give the reasons for doing so. 
  I am, exercising my free power of choice; hereby give my consent to be 
included as a subject in the clinical trial of “ILAGU SEENA CHOORANAM”for the 
treatment of “VENPADAI” 
Informant Signature:………. 
Date:        Informant Name: …………. 
Place:        Patient Name:………………. 
Signature of Witness     Relationship:………………… 
xli 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAIPOST GRADUATE DEPARTMENT OF 
 
KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “VENPADAI”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS ILAGU SEENA CHOORANAM 
 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: …………. 
Date of Completion :…………. Informant: …………. Reliability :  …………… 
 
FORM IVB – WITHDRAWAL 
 
Date of Trial commencement  : 
Date of withdrawal from trial  : 
Reason (s) for withdrawal   : Yes /No 
Long absence at reporting   : Yes /No 
Irregular treatment    : Yes /No 
Shift of locality    : Yes /No 
Complication adverse reactions if any: Yes /No 
Exacerbation of symptoms   : Yes /No 













FORM IV-C – PATIENT INFORMATION SHEET 
Name of the principal investigator: 
……………………………………………………. 
Name of the institution  :  GOVERNMENT SIDDHA MEDICAL  
         COLLEGE&HOSPITAL, 
 Palayamkottai 
Information sheet for patients participating in the open clinical, trial  
 
1, _____________________________________ Studying as PG Scholar at  
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI  is doing a trail on the study “VENPADAI” . It  is a most 
common  disease in children. In this regard, I am in a need to ask you few questions. I 
will maintain confidentially of your comments and data obtained. There will be no risk 
of disclosing your identity and no physical, psychological or professional risk is 
involved by taking part in this study. Taking part in this study is voluntary. No 
compensation will be paid to you for taking part in this study.  
You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part 
in the study may be of benefit to the community, as it may help us to understand the 
problem of defaulters and potential solutions.  
If you agree your child to be a participate in this study, he/she will be included in the 
study primarily by signing the concern form and then you will be given the internal 





Signature of Guide:              Signature of Principal Investigator: 
 
 




GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY ON “VENPADAI”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS ILAGU SEENA CHOORANAM 
FORM IVD- DIETARY ADVICE FORM 
 
S.I.No: ………….    OP/IP No: …………  Name: ……………… 
Age: ……………. Gender:  …………..   Date of Enrollment: …… 
Date of Completion :……… Informant: …………. Reliability :  …………… 
 
The following diet to be taken: The following food should be avoided 
• Drink adequatewater 
• Green leafy vegetables 
• Fig fruit  






• Seafood (sardines) 
• Avoid bitter and sour taste foods  
• Agathi greens 
• Spicy foods 
• Chicken 




Signature of the Investigator: 
 
Signature of the Guide : 
    




Form – IVE 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
Reporting Form For Suspected Adverse Reactions to Siddha Drugs 
 
Please Note: i. All Consumers/Patients and reporters information will remain  
          confidential.  
  ii. It is requested to report all suspected reactions to the concerned,  
                            even if it does not have complete data, as soon as possible.  
 
Peripheral centrecode :      State : 





Father Name  
 









Date of Birth/Age 




2. Description of the suspected adverse reactions please complete boxes below 





Description of reaction  
 
 
 Geographical area: 
xlv 
 
3. List of all medicines/Formulations including drugs of other systems used by the 









Diagnosis for which 










     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
1) 
Details Drug  




unit and batch no. and date 
 
c) Expiry date  
d) Purchased and 
obtained from 
 
e) Composition of 
the formulation / part of 




2) Dietary restrictions if any 
3) Whether the drug is consumed under institutionally qualified medical 
     supervision or used as self medication 
xlvi 
 
4) Any other relevant information  
5. Treatment provided for adverse reaction: 
 
 
6. The result of the adverse reaction /side effect / untoward effects ( Please 




Unknown Fatal If fatal 
Date of death: 
Severe Yes /No Reaction abated after drug stopped or dose reduced 
 




Was the patient admitted to hospital? If 
yes, give name and address of hospital  
 
 
7. Any laboratory investigation done to evaluate other possibilities? If yes specify: 
 
 
8. Whether the patient is suffering with any chronic disorders? 
 
Hepatic    Renal  Cardiac Diabetes Malnutrition  
 
 
Any Others  
 
9. H/O previous allergies /Drug reactions: 
 




Type (please tick):Nurse/Doctor/Pharmacist/Health 
















Signature of the reporter      Date : 
 




Government Siddha Medical College &Hospital, Palayamkottai, Post Graduate 




 The co-ordinator 
Pharmacovigilance 
Department, 






This Filled- in ADR report may be send within one month of observation / 



















Signature of Investigator: 
 









Who can report?  
 Any health care professionals like Siddha Doctors 
/Nurses /Siddha Pharmacists /Patients Etc.,   
What to report? 
 All reactions, Drug interactions 
Confidentiality  
 The patient’s identify will be held in strict confidence 




GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
BRANCH IV – KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI - 627 002. 
Form IVF -ADMISSION – DISCHARGE SHEET 
Name of the medical unit  :    Nationality  : 
I.P.No     :     Religion  : 
Bed No    :    Informant  : 
Name     :    Date of Admission : 
Age/Sex    :    Date of Discharge : 
Occupation(parents)   :    No. of days treated  : 
Income(parents)   :    Diagnosis  : 
S.No 
 





1 Hypo pigmented patch   
2 Loss of appetite   
3 Constipation   





Date:            
           







GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAI 
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY ON “VENPADAI”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS ILAGU SEENA CHOORANAM 
FORM V-DRUG COMPLIANCE 
 
S.I.No: ………….  OP/IP No: ………… Name: ……………… 
Age: …………….  Gender: …………..  Date of Enrollment: …………. 
Date of Completion :…………. Informant:………..   Reliability :  …………… 
 
NAME OF THE DRUG   : ILAGU SEENA CHOORANAM 
FORM OF THE DRUG    : CHOORANAM 
ADMINISTRATION &ADJUVANT : PER ORAL  
DOSE & DURATION    : 1-2GM FOR 27 DAYS 
NO OF DRUG PACKS GIVEN   : ________________ 
NO OF DRUG PACKS  RETURNED : ________________ 
DAY 
DATE OF DRUG 
INTAKE 
MORNING EVENING 
DAY 1    
DAY 2    
DAY 3    
DAY 4    
DAY 5    
DAY 6    
DAY 7    
DAY 8    
DAY 9    
li 
 
DAY 10    
DAY 11    
DAY 12    
DAY 13    
DAY14    
DAY 15    
DAY 16    
DAY 17    
DAY 18    
DAY19    
DAY20    
DAY 21    
DAY 22    
DAY 23    
DAY 24    
DAY 25    
DAY 26    
DAY 27    
 
 
Date :                                                       Signature of Principal Investigator:  
 
 
Signature of the Guide: 
 
 
Signature of  HOD : 
